

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q

(Mark One)

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Quarterly Period ended September 30, 2022
Or

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Transition Period from _____ to _____
Commission file number: 001-33626

GENPACT LIMITED

(Exact name of registrant as specified in its charter)

Bermuda
(State or other jurisdiction of
incorporation or organization)

98-0533350
(I.R.S. Employer
Identification No.)

**Canon's Court
22 Victoria Street
Hamilton HM 12
Bermuda
(441) 298-3300**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive office)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common shares, par value \$0.01 per share	G	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

As of November 3, 2022, there were 183,258,135 common shares, par value \$0.01 per share, of the registrant issued and outstanding.

TABLE OF CONTENTS

Item No.

Page No.

PART I

Financial Information

1.	<u>Unaudited Consolidated Financial Statements</u>	
	<u>Consolidated Balance Sheets as of December 31, 2021 and September 30, 2022</u>	3
	<u>Consolidated Statements of Income for the three and nine months ended September 30, 2021 and 2022</u>	4
	<u>Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2021 and 2022</u>	5
	<u>Consolidated Statements of Equity for the three and nine months ended September 30, 2021 and 2022</u>	6
	<u>Consolidated Statements of Cash Flows for the nine months ended September 30, 2021 and 2022</u>	10
	<u>Notes to the Consolidated Financial Statements</u>	11
2.	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	50
3.	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	71
4.	<u>Controls and Procedures</u>	72

PART II

Other Information

1.	<u>Legal Proceedings</u>	73
1A.	<u>Risk Factors</u>	73
2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	73
6.	<u>Exhibits</u>	74

SIGNATURES

75

PART I - FINANCIAL INFORMATION

Item 1. Unaudited Consolidated Financial Statements

GENPACT LIMITED AND ITS SUBSIDIARIES
Consolidated Balance Sheets
(Unaudited)
(In thousands, except per share data and share count)

Assets	Notes	As of December 31, 2021	As of September 30, 2022
Current assets			
Cash and cash equivalents		\$ 899,458	\$ 518,680
Accounts receivable, net of allowance for credit losses of \$24,329 and \$20,437 as of December 31, 2021 and September 30, 2022, respectively	4	887,742	994,250
Prepaid expenses and other current assets	7	134,441	229,825
Assets of business held for sale	8	\$ —	\$ 15,621
Total current assets		\$ 1,921,641	\$ 1,758,376
Property, plant and equipment, net	9	215,089	180,379
Operating lease right-of-use assets		270,603	191,371
Deferred tax assets	23	106,322	111,932
Intangible assets, net	10	169,635	101,226
Goodwill	10	1,731,027	1,680,932
Contract cost assets	20	238,794	218,137
Other assets, net of allowance for credit losses of \$3,711 and \$3,198 as of December 31, 2021 and September 30, 2022, respectively		322,158	294,319
Total assets		\$ 4,975,269	\$ 4,536,672
Liabilities and equity			
Current liabilities			
Short-term borrowings	11	\$ —	\$ 200,000
Current portion of long-term debt	12	383,433	535,142
Accounts payable		24,984	27,925
Income taxes payable	23	47,353	107,172
Accrued expenses and other current liabilities	13	791,440	700,484
Operating leases liability		61,591	53,976
Liabilities of business held for sale	8	\$ —	\$ 8,410
Total current liabilities		\$ 1,308,801	\$ 1,633,109
Long-term debt, less current portion	12	1,272,476	746,613
Operating leases liability		247,707	186,057
Deferred tax liabilities	23	3,942	3,634
Other liabilities	14	245,210	235,413
Total liabilities		\$ 3,078,136	\$ 2,804,826
Shareholders' equity			
Preferred shares, \$0.01 par value, 250,000,000 authorized, none issued		—	—
Common shares, \$0.01 par value, 500,000,000 authorized, \$185,336,357 and 183,008,135 issued and outstanding as of December 31, 2021 and September 30, 2022, respectively		1,847	1,825
Additional paid-in capital		1,717,165	1,740,271
Retained earnings		732,474	745,172
Accumulated other comprehensive income (loss)		(554,353)	(755,422)
Total equity		\$ 1,897,133	\$ 1,731,846
Commitments and contingencies	24		
Total liabilities and equity		\$ 4,975,269	\$ 4,536,672

See accompanying notes to the Consolidated Financial Statements.

GENPACT LIMITED AND ITS SUBSIDIARIES
Consolidated Statements of Income
(Unaudited)
(In thousands, except per share data and share count)

	Notes	Three months ended September 30,		Nine months ended September 30,	
		2021	2022	2021	2022
Net revenues	20	\$ 1,015,737	\$ 1,111,037	\$ 2,949,934	\$ 3,268,627
Cost of revenue		653,686	717,219	1,887,596	2,117,437
Gross profit		\$ 362,051	\$ 393,818	\$ 1,062,338	\$ 1,151,190
<i>Operating expenses:</i>					
Selling, general and administrative expenses		215,957	231,436	620,857	701,828
Amortization of acquired intangible assets	10	13,898	10,604	44,624	32,805
Other operating (income) expense, net	21	(93)	20,937	(217)	42,157
Income from operations		\$ 132,289	\$ 130,841	\$ 397,074	\$ 374,400
Foreign exchange gains (losses), net		2,733	3,867	11,529	9,312
Interest income (expense), net	22	(12,765)	(13,399)	(38,198)	(36,691)
Other income (expense), net		1,480	(235)	8,966	(4,902)
Income before income tax expense		\$ 123,737	\$ 121,074	\$ 379,371	\$ 342,119
Income tax expense	23	21,351	25,231	83,008	78,427
Net income		\$ 102,386	\$ 95,843	\$ 296,363	\$ 263,692
<i>Earnings per common share</i>					
Basic	18	\$ 0.55	\$ 0.52	\$ 1.58	\$ 1.43
Diluted		\$ 0.53	\$ 0.51	\$ 1.54	\$ 1.40
<i>Weighted average number of common shares used in computing earnings per common share</i>					
Basic	18	187,856,026	183,312,013	187,945,234	184,456,047
Diluted		193,159,929	187,399,204	192,885,252	188,274,420

See accompanying notes to the Consolidated Financial Statements.

GENPACT LIMITED AND ITS SUBSIDIARIES
Consolidated Statements of Comprehensive Income (Loss)
(Unaudited)
(In thousands)

	Three months ended September 30,		Nine months ended September 30,	
	2021	2022	2021	2022
Net income (loss)	\$ 102,386	\$ 95,843	\$ 296,363	\$ 263,692
Other comprehensive income:				
Currency translation adjustments	(9,043)	(71,092)	(36,721)	(179,933)
Net income (loss) on cash flow hedging derivatives, net of taxes (Note 6)	7,789	(14,198)	10,321	(23,056)
Retirement benefits, net of taxes	497	374	2,128	1,920
Other comprehensive income (loss)	(757)	(84,916)	(24,272)	(201,069)
Comprehensive income (loss)	\$ 101,629	\$ 10,927	\$ 272,091	\$ 62,623

See accompanying notes to the Consolidated Financial Statements.

GENPACT LIMITED AND ITS SUBSIDIARIES
Consolidated Statements of Equity
For the three months ended September 30, 2021
(Unaudited)
(In thousands, except share count)

	Common shares					Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total Equity
	No. of Shares	Amount	Additional Paid-in Capital					
Balance as of July 1, 2021	187,350,298	\$ 1,869	\$ 1,637,756	\$ 748,199	\$ (568,855)	\$ 1,838,969		
Issuance of common shares on exercise of options (Note 16)	511,813	5	11,732	—	—	11,737		
Issuance of common shares under the employee stock purchase plan (Note 16)	60,374	1	2,818	—	—	2,819		
Net settlement on vesting of restricted share units (Note 16)	134,086	1	(3,535)	—	—	(3,534)		
Stock-based compensation expense (Note 16)	—	—	21,485	—	—	21,485		
Others	—	—	(6)	—	—	(6)		
Comprehensive income (loss):								
Net income (loss)	—	—	—	102,386	—	102,386		
Other comprehensive income (loss)	—	—	—	—	(757)	(757)		
Dividend (\$0.1075 per common share, Note 17)	—	—	—	(20,213)	—	(20,213)		
Balance as of September 30, 2021	188,056,571	\$ 1,876	\$ 1,690,250	\$ 830,372	\$ (569,612)	\$ 1,952,886		

See accompanying notes to the Consolidated Financial Statements.

GENPACT LIMITED AND ITS SUBSIDIARIES
Consolidated Statements of Equity
For the nine months ended September 30, 2021
(Unaudited)
(In thousands, except share count)

	Common shares					Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total Equity
	No. of Shares	Amount	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)			
Balance as of January 1, 2021	189,045,661	\$ 1,885	\$ 1,636,026	\$ 741,658	\$ (545,340)	\$ 1,834,229		
Issuance of common shares on exercise of options (Note 16)	1,020,125	11	20,902	—	—	20,913		
Issuance of common shares under the employee stock purchase plan (Note 16)	216,378	2	8,871	—	—	8,873		
Net settlement on vesting of restricted share units (Note 16)	264,376	3	(5,845)	—	—	(5,842)		
Net settlement on vesting of performance units (Note 16)	1,102,440	11	(28,302)	—	—	(28,291)		
Stock repurchased and retired (Note 17)	(3,592,409)	(36)	—	(147,116)	—	(147,152)		
Expenses related to stock purchase (Note 17)	—	—	—	(72)	—	(72)		
Stock-based compensation expense (Note 16)	—	—	58,604	—	—	58,604		
Others	—	—	(6)	—	—	(6)		
Comprehensive income (loss):								
Net income (loss)	—	—	—	296,363	—	296,363		
Other comprehensive income (loss)	—	—	—	—	(24,272)	(24,272)		
Dividend (\$0.3225 per common share, Note 17)	—	—	—	(60,461)	—	(60,461)		
Balance as of September 30, 2021	188,056,571	\$ 1,876	\$ 1,690,250	\$ 830,372	\$ (569,612)	\$ 1,952,886		

GENPACT LIMITED AND ITS SUBSIDIARIES
Consolidated Statements of Equity
For the three months ended September 30, 2022
(Unaudited)
(In thousands, except share count)

	Common shares					Accumulated Other Comprehensive Income (Loss)	Total Equity
	No. of Shares	Amount	Additional Paid-in Capital	Retained Earnings			
Balance as of July 1, 2022	183,483,736	\$ 1,830	\$ 1,716,895	\$ 702,219	\$ (670,506)	\$ 1,750,438	
Issuance of common shares on exercise of options (Note 16)	60,000	—	1,573	—	—	1,573	
Issuance of common shares under the employee stock purchase plan (Note 16)	71,499	1	3,022	—	—	3,023	
Net settlement on vesting of restricted share units (Note 16)	19,992	—	(421)	—	—	(421)	
Stock repurchased and retired (Note 17)	(627,092)	(6)	—	(30,005)	—	(30,011)	
Expenses related to stock purchase (Note 17)	—	—	—	(12)	—	(12)	
Stock-based compensation expense (Note 16)	—	—	19,202	—	—	19,202	
Comprehensive income (loss):							
Net income (loss)	—	—	—	95,843	—	95,843	
Other comprehensive income (loss)	—	—	—	—	(84,916)	(84,916)	
Dividend (\$0.1250 per common share, Note 17)	—	—	—	(22,873)	—	(22,873)	
Balance as of September 30, 2022	183,008,135	\$ 1,825	\$ 1,740,271	\$ 745,172	\$ (755,422)	\$ 1,731,846	

See accompanying notes to the Consolidated Financial Statements.

GENPACT LIMITED AND ITS SUBSIDIARIES
Consolidated Statements of Equity
For the nine months ended September 30, 2022
(Unaudited)
(In thousands, except share count)

	Common shares					Accumulated Other Comprehensive Income (Loss)	Total Equity
	No. of Shares	Amount	Additional Paid-in Capital	Retained Earnings	Retained Earnings		
Balance as of January 1, 2022	185,336,357	\$ 1,847	\$ 1,717,165	\$ 732,474	\$ (554,353)	\$ 1,897,133	
Issuance of common shares on exercise of options (Note 16)	110,000	1	2,955	—	—	2,956	
Issuance of common shares under the employee stock purchase plan (Note 16)	253,377	3	10,083	—	—	10,086	
Net settlement on vesting of restricted share units (Note 16)	74,934	1	(422)	—	—	(421)	
Net settlement on vesting of performance units (Note 16)	1,300,511	13	(44,404)	—	—	(44,391)	
Stock repurchased and retired (Note 17)	(4,067,044)	(40)	—	(181,971)	—	(182,011)	
Expenses related to stock purchase (Note 17)	—	—	—	(81)	—	(81)	
Stock-based compensation expense (Note 16)	—	—	54,894	—	—	54,894	
Comprehensive income (loss):							
Net income (loss)	—	—	—	263,692	—	263,692	
Other comprehensive income (loss)	—	—	—	—	(201,069)	(201,069)	
Dividend (\$0.3750 per common share, Note 17)	—	—	—	(68,942)	—	(68,942)	
Balance as of September 30, 2022	183,008,135	\$ 1,825	\$ 1,740,271	\$ 745,172	\$ (755,422)	\$ 1,731,846	

See accompanying notes to the Consolidated Financial Statements.

GENPACT LIMITED AND ITS SUBSIDIARIES
Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)

	Nine months ended September 30,	
	2021	2022
Operating activities		
Net income	\$ 296,363	\$ 263,692
<i>Adjustments to reconcile net income to net cash provided by operating activities:</i>		
Depreciation and amortization	82,344	68,169
Amortization of debt issuance costs	1,969	1,825
Amortization of acquired intangible assets	44,624	32,805
Write-down of intangible assets and property, plant and equipment	915	1,377
Impairment charge on intangible assets and goodwill held-for-sale	—	21,426
Allowance for credit losses	2,412	1,045
Unrealized (gain) loss on revaluation of foreign currency asset/liability	(4,252)	2,150
Stock-based compensation expense	58,604	54,894
Deferred tax benefit	(6,236)	(7,655)
Write-down of operating right-of-use assets and other assets	—	20,307
Others, net	806	323
Change in operating assets and liabilities:		
Increase in accounts receivable	(78,626)	(121,038)
(Increase) decrease in prepaid expenses, other current assets, contract cost assets, operating lease right-of-use assets and other assets	43,071	(57,940)
Increase in accounts payable	11,138	6,755
Decrease in accrued expenses, other current liabilities, operating leases liabilities and other liabilities	(74,085)	(132,524)
Increase in income taxes payable	68,430	58,431
Net cash provided by operating activities	\$ 447,477	\$ 214,042
Investing activities		
Purchase of property, plant and equipment	(31,385)	(35,312)
Payment for internally generated intangible assets (including intangibles under development)	(3,907)	(2,972)
Proceeds from sale of property, plant and equipment	4,511	58
(Payment)/ refund for business acquisitions, net of cash acquired	(6,613)	973
Proceed from sale of investment	142	—
Net cash used for investing activities	\$ (37,252)	\$ (37,253)
Financing activities		
Repayment of finance lease obligations	(8,659)	(10,305)
Payment of debt issuance costs	(3,018)	—
Proceeds from long-term debt	350,000	—
Repayment of long-term debt	(25,500)	(375,500)
Proceeds from short-term borrowings	—	250,000
Repayment of short-term borrowings	(250,000)	(50,000)
Proceeds from issuance of common shares under stock-based compensation plans	29,786	13,042
Payment for net settlement of stock-based awards	(33,467)	(44,942)
Payment of earn-out consideration	(2,556)	(2,437)
Dividend paid	(60,461)	(68,942)
Payment for stock repurchased and retired (including expenses related to stock repurchase)	(147,224)	(182,092)
Others	(6)	—
Net cash used for financing activities	\$ (151,105)	\$ (471,176)
Effect of exchange rate changes	(17,085)	(86,391)
Net increase/(decrease) in cash and cash equivalents	259,120	(294,387)
Cash and cash equivalents at the beginning of the period	680,440	899,458
Cash and cash equivalents at the end of the period	\$ 922,475	\$ 518,680
Supplementary information		
Cash paid during the period for interest	\$ 25,715	\$ 30,430
Cash paid during the period for income taxes, net of refund	\$ 38,040	\$ 114,343

See accompanying notes to the Consolidated Financial Statements.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

1. Organization

The Company is a global professional services firm that drives digitally-led innovation and runs digitally-enabled intelligent operations for its clients, guided by its experience running thousands of processes for hundreds of Fortune Global 500 clients. The Company has over 117,700 employees serving clients in key industry verticals from more than 30 countries.

2. Summary of significant accounting policies

(a) Basis of preparation and principles of consolidation

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") and the rules and regulations of the Securities and Exchange Commission (the "SEC") for reporting on Form 10-Q. Accordingly, they do not include certain information and note disclosures required by generally accepted accounting principles for annual financial reporting and should be read in conjunction with the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying consolidated financial statements reflect all adjustments that management considers necessary for a fair presentation of the results of operations for these periods.

The accompanying financial statements have been prepared on a consolidated basis and reflect the financial statements of Genpact Limited, a Bermuda company, and all of its subsidiaries that are more than 50% owned and controlled. When the Company does not have a controlling interest in an entity but exerts significant influence over the entity, the Company applies the equity method of accounting. All intercompany transactions and balances are eliminated in consolidation.

(b) Use of estimates

The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements. Significant items subject to such estimates and assumptions include the useful lives of property, plant and equipment, intangible assets and goodwill, revenue recognition, allowance for credit losses, valuation allowances for deferred tax assets, the valuation of derivative financial instruments, the measurement of lease liabilities and right-of-use ("ROU") assets, measurements of stock-based compensation, assets and obligations related to employee benefits, the nature and timing of the satisfaction of performance obligations, the standalone selling price of performance obligations, variable consideration, other obligations for revenue recognition, income tax uncertainties and other contingencies. Management believes that the estimates used in the preparation of the consolidated financial statements are reasonable, and management has made assumptions about the possible effects of the ongoing COVID-19 pandemic on critical and significant accounting estimates. Although these estimates and assumptions are based upon management's best knowledge of current events and actions, actual results could differ from these estimates. Any changes in estimates are adjusted prospectively in the Company's consolidated financial statements.

(c) Business combinations, goodwill and other intangible assets

The Company accounts for its business combinations using the acquisition method of accounting in accordance with Accounting Standard Codification ("ASC") Topic 805, Business Combinations, by recognizing the identifiable tangible and intangible assets acquired and liabilities assumed, and any non-controlling interest in the acquired business, measured at their acquisition date fair values. Contingent consideration is included within the acquisition cost and is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is re-measured to fair value as of each reporting date until the contingency is resolved. Changes in fair value are recognized in earnings. All assets and liabilities of the acquired businesses, including goodwill, are assigned to reporting units. Acquisition-related costs are expensed as incurred under selling, general and administrative expenses.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

2. Summary of significant accounting policies (Continued)

Goodwill represents the cost of acquired businesses in excess of the fair value of identifiable tangible and intangible net assets purchased. Goodwill is not amortized but is tested for impairment at least on an annual basis on December 31, based on a number of factors, including operating results, business plans and future cash flows. The Company performs an assessment of qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Based on the assessment of events or circumstances, the Company performs a quantitative assessment of goodwill impairment if it determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, based on the quantitative impairment analysis, the carrying value of the goodwill of a reporting unit exceeds the fair value of such goodwill, an impairment loss is recognized in an amount equal to the excess. In addition, the Company performs a qualitative assessment of goodwill impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. See Note 10 for information and related disclosures.

Intangible assets acquired individually or with a group of other assets or in a business combination and developed internally are carried at cost less accumulated amortization and accumulated impairment loss based on their estimated useful lives as follows:

Customer-related intangible assets	1 - 9 years
Marketing-related intangible assets	1 - 8 years
Technology-related intangible assets	2 - 10 years

Intangible assets are amortized over their estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are consumed or otherwise realized.

In business combinations where the fair value of identifiable tangible and intangible net assets purchased exceeds the cost of the acquired business, the Company recognizes the resulting gain under "Other operating (income) expense, net" in the consolidated statements of income.

The Company also capitalizes certain software and technology-related development costs incurred in connection with developing or obtaining software or technology for sale/lease to customers when the initial design phase is completed and commercial and technological feasibility has been established. Any development cost incurred before technological feasibility is established is expensed as incurred as research and development costs. Technological feasibility is established upon completion of a detailed design program or, in its absence, completion of a working model. Capitalized software and technology costs include only (i) external direct costs of materials and services utilized in developing or obtaining software and technology and (ii) compensation and related benefits for employees who are directly associated with the project.

Costs incurred in connection with developing or obtaining software or technology for sale/lease to customers which are under development and not put to use are disclosed under "intangible assets under development." Advances paid towards the acquisition of intangible assets outstanding as of each balance sheet date are disclosed under "intangible assets under development."

Capitalized software and technology costs are included in intangible assets under technology-related intangible assets on the Company's balance sheet and are amortized on a straight-line basis when placed into service over the estimated useful lives of the software and technology.

The Company evaluates the remaining useful life of intangible assets that are being amortized at each reporting period wherever events and circumstances warrant a revision to the remaining period of amortization, and the remaining carrying amount of the intangible asset is amortized prospectively over that revised remaining useful life.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

2. Summary of significant accounting policies (Continued)

(d) Financial instruments and concentration of credit risk

Financial instruments that potentially subject the Company to concentration of credit risk are reflected principally in cash and cash equivalents, derivative financial instruments and accounts receivable. The Company places its cash and cash equivalents and derivative financial instruments with corporations and banks with high investment grade ratings, limits the amount of credit exposure with any one corporation or bank and conducts ongoing evaluations of the creditworthiness of the corporations and banks with which it does business. To reduce its credit risk on accounts receivable, the Company conducts ongoing credit evaluations of its customers.

(e) Accounts receivable

Accounts receivable are recorded at the invoiced or to be invoiced amount and do not bear interest. Amounts collected on trade accounts receivable are included in net cash provided by operating activities in the consolidated statements of cash flows. The Company maintains an allowance for current expected credit losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical losses which are adjusted to current market conditions and a reasonable and supportable forecast. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

The Company uses revolving accounts receivable-based facilities in the normal course of business as part of managing its cash flows. The Company accounts for receivables sold under these facilities as a sale of financial assets pursuant to ASC 860 "Transfers and Servicing" and de-recognizes these receivables, as well as the related allowances, from its balance sheets. Generally, the fair value of accounts receivable sold approximates their book value due to their short-term nature, and any gains or losses on the sale of these receivables are recorded at the time of transfer and included under "interest income (expense), net" in the Company's consolidated statements of income.

(f) Revenue Recognition

The Company derives its revenue primarily from business process management services, including analytics, consulting and related digital solutions and information technology services, which are provided primarily on a time-and-material, transaction or fixed-price basis. The Company recognizes revenue upon the transfer of control of promised services to its customers in an amount that reflects the consideration the Company expects to receive in exchange for those services. Revenues from services rendered under time-and-materials and transaction-based contracts are recognized as the services are provided. The Company's fixed-price contracts include contracts for customization of applications, maintenance and support services. Revenues from these contracts are recognized ratably over the term of the agreement. The Company accrues for revenue and unbilled receivables for services rendered between the last billing date and the balance sheet date.

The Company's contracts with its customers also include incentive payments received for discrete benefits delivered or promised to be delivered to the customer or service level agreements that could result in credits or refunds to the customer. Revenues relating to such arrangements are accounted for as variable consideration when the amount of revenue to be recognized can be estimated to the extent that it is probable that a significant reversal of any incremental revenue will not occur.

The Company records deferred revenue attributable to certain process transition activities where such activities do not represent separate performance obligations. Revenues relating to such transition activities are classified under contract liabilities and subsequently recognized ratably over the period in which the related services are performed. Costs relating to such transition activities are fulfillment costs which are directly related to the contract and result in the generation or enhancement of resources. Such costs are expected to be recoverable under the contract and are therefore classified as contract cost assets and recognized ratably over the estimated expected period of benefit under cost of revenue.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

2. Summary of significant accounting policies (Continued)

Revenues are reported net of value-added tax, business tax and applicable discounts and allowances. Reimbursements of out-of-pocket expenses received from customers have been included as part of revenues.

Revenue for performance obligations that are satisfied over time is recognized in accordance with the methods prescribed for measuring progress. The input (cost expended) method has been used to measure progress towards completion as there is a direct relationship between input and the satisfaction of a performance obligation. Provisions for estimated losses, if any, on uncompleted contracts are recorded in the period in which such losses become probable based on the current contract estimates.

The Company enters into multiple-element revenue arrangements in which a customer may purchase a combination of products or services. The Company determines whether each product or service promised to a customer is capable of being distinct, and is distinct in the context of the contract. If not, the promised products or services are combined and accounted for as a single performance obligation. In the event of a multiple-element revenue arrangement, the Company allocates the arrangement consideration to separately identifiable performance obligations based on their relative stand-alone selling prices.

Certain contracts may include offerings such as sale of licenses, which may be perpetual or subscription-based. Revenue from distinct perpetual licenses is recognized upfront at the point in time when the software is made available to the customer. Revenue from distinct, non-cancellable, subscription-based licenses is recognized at the point in time it is transferred to the customer. Revenue from any associated maintenance or ongoing support services is recognized ratably over the term of the contract. For a combined software license/services performance obligation, revenue is recognized over the period that the services are performed.

All incremental and direct costs incurred for acquiring contracts, such as certain sales commissions, are classified as contract cost assets. Such costs are amortized over the expected period of benefit and recorded under selling, general and administrative expenses.

Other upfront fees paid to customers are classified as contract assets. Such fees are amortized over the expected period of benefit and recorded as an adjustment to the transaction price and deducted from revenue.

Timing of revenue recognition may differ from the timing of invoicing. If a payment is received in respect of services prior to the delivery of services, the payment is recognized as an advance from the customer and classified as a contract liability. Contract assets and contract liabilities relating to the same customer contract are offset against each other and presented on a net basis in the consolidated financial statements.

Significant judgements

The Company often enters into contracts with its customers that include promises to transfer multiple products and services to the customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately rather than together may require significant judgement.

Judgement is also required to determine the standalone selling price for each distinct performance obligation. In instances where the standalone selling price is not directly observable, it is determined using information that may include market conditions and other observable inputs.

Customer contracts sometimes include incentive payments received for discrete benefits delivered to the customer or service level agreements that could result in credits or refunds to the customer. Such amounts are estimated at contract inception and are adjusted at the end of each reporting period as additional information becomes available only to the extent that it is probable that a significant reversal of any incremental revenue will not occur.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

2. Summary of significant accounting policies (Continued)

(g) Leases

At the inception of a contract, the Company assesses whether the contract is, or contains, a lease. The Company's assessment is based on whether: (1) the contract involves the use of a distinct identified asset, (2) the Company obtains the right to substantially all the economic benefit from the use of the asset throughout the term of the contract, and (3) the Company has the right to direct the use of the asset. At the inception of a lease, the consideration in the contract is allocated to each lease component based on its relative standalone price to determine the lease payments.

Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (1) the lease transfers ownership of the asset by the end of the lease term, (2) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (3) the lease term is for a major part of the remaining useful life of the asset or (4) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any one of the above criteria.

For all leases at the lease commencement date, a ROU asset and a lease liability are recognized. The lease liability represents the present value of the lease payments under the lease. Lease liabilities are initially measured at the present value of the lease payments not yet paid, discounted using the discount rate for the lease at the lease commencement. The lease liabilities are subsequently measured on an amortized cost basis. The lease liability is adjusted to reflect interest on the liability and the lease payments made during the period. Interest on the lease liability is determined as the amount that results in a constant periodic discount rate on the remaining balance of the liability.

The ROU asset represents the right to use the leased asset for the lease term. The ROU asset for each lease initially includes the amount of the initial measurement of the lease liability adjusted for any lease payments made to the lessor at or before the commencement date, accrued lease liabilities and any lease incentives received or any initial direct costs incurred by the Company.

The ROU asset of finance leases is subsequently measured at cost, less accumulated amortization and any accumulated impairment losses. The ROU asset of operating leases is subsequently measured from the carrying amount of the lease liability at the end of each reporting period, and is equal to the carrying amount of lease liabilities adjusted for (1) unamortized initial direct costs, (2) prepaid/(accrued) lease payments and (3) the unamortized balance of lease incentives received.

The carrying value of ROU assets is reviewed for impairment, similar to long-lived assets, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable.

The Company has elected to not separate lease and non-lease components for all of its leases and to use the recognition exemptions for lease contracts that, at commencement date, have a lease term of 12 months or less and do not contain a purchase option ("short-term leases").

Significant judgements

The Company determines the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised. Under certain of its leases, the Company has a renewal and termination option to lease assets for additional terms between one and ten years. The Company applies judgement in evaluating whether it is reasonably certain to exercise the option to renew or terminate the lease. The Company considers all relevant factors that create an economic incentive for it to exercise the renewal or termination option. After the commencement date, the Company reassesses the lease term if there is a significant event or change in circumstances that is within the Company's control and affects its ability to exercise (or not to exercise) the option to renew or terminate.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

2. Summary of significant accounting policies (Continued)

The Company has applied an incremental borrowing rate for the purpose of computing lease liabilities based on the remaining lease term and the rates prevailing in the jurisdictions where leases were executed.

(h) Cost of revenue

Cost of revenue primarily consists of salaries and benefits (including stock-based compensation), recruitment, training and related costs of employees who are directly responsible for the performance of services for customers, their supervisors and certain support personnel who may be dedicated to a particular client or a set of processes. It also includes operational expenses, which consist of facilities maintenance expenses, travel and living expenses, rent, IT expenses, and consulting and certain other expenses. Consulting charges represent the cost of consultants and contract resources with specialized skills who are directly responsible for the performance of services for clients and travel and other billable costs related to the Company's clients. It also includes depreciation of property, plant and equipment, and amortization of intangible and ROU assets which are directly related to providing services that generate revenue.

(i) Selling, general and administrative expenses

Selling, general and administrative ("SG&A") expenses consist of expenses relating to salaries and benefits (including stock-based compensation) as well as costs related to recruitment, training and retention of senior management and other support personnel in enabling functions such as human resources, finance, legal, marketing, sales and sales support, and other support personnel. The operational costs component of SG&A expenses also includes travel and living costs for such personnel. SG&A expenses also include acquisition-related costs, legal and professional fees (which represent the costs of third party legal, tax, accounting and other advisors), investment in research and development, digital technology, advanced automation and robotics, and an allowance for credit losses. It also includes depreciation of property, plant and equipment, and amortization of intangibles and ROU assets other than those included in cost of revenue.

(j) Credit losses

An allowance for credit losses is recognized for all debt instruments other than those held at fair value through profit or loss. The Company pools its accounts receivable (other than deferred billings) based on similar risk characteristics in estimating expected credit losses. Credit losses for accounts receivable are based on the roll-rate method, and the Company recognizes a loss allowance based on lifetime expected credit losses at each reporting date. The Company has established a provision matrix based on historical credit loss experience, adjusted for forward-looking factors and the economic environment. The Company believes the most relevant forward-looking factors are economic environment, gross domestic product, inflation rates and unemployment rates for each of the countries in which the Company or its customers operate, and accordingly the Company adjusts historical loss rates based on expected changes in these factors. At every reporting date, observed historical default rates are updated to reflect changes in the Company's forward-looking estimates.

Credit losses for other financial assets and deferred billings are based on the discounted cash flow ("DCF") method. Under the DCF method, the allowance for credit losses reflects the difference between the contractual cash flows due in accordance with the contract and the present value of the cash flows expected to be collected. The expected cash flows are discounted at the effective interest rate of the financial asset. Such allowances are based on the credit losses expected to arise over the life of the asset which includes consideration of prepayments based on the Company's expectation as of the balance sheet date.

A financial asset is written off when it is deemed uncollectible and there is no reasonable expectation of recovering the contractual cash flows. Expected recoveries of amounts previously written off, not to exceed the aggregate amounts previously written off, are included in determining the allowance at each reporting period.

Credit losses are presented as a credit loss expense within "Selling, general and administrative expenses." Subsequent recoveries of amounts previously written off are credited against the same line item.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

2. Summary of significant accounting policies (Continued)

(k) Reclassification

Certain reclassifications have been made in the consolidated financial statements of prior periods to conform to the classification used in the current period. The impact of such reclassifications on the consolidated financial statements is not material.

(l) Impairment of long-lived assets

Long-lived assets, including certain intangible assets, to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Such assets are required to be tested for impairment if the carrying amount of the assets is higher than the future undiscounted net cash flows expected to be generated by the assets. The impairment amount to be recognized is measured as the amount by which the carrying value of the assets exceeds their fair value. The Company determines fair value by using a discounted cash flow approach.

(m) Assets held for sale

A long-lived asset (or a disposal group for a long-lived asset comprising a group of assets and related liabilities) is classified as held for sale if it is highly probable that the asset will be recovered through sale rather than continuing use.

The Company records assets held for sale at the lower of its carrying value or fair value less costs to sell. The following criteria are used to determine if a business is held for sale: (i) management, having the authority to approve a sale, commits to a plan to sell; (ii) the business is available for immediate sale in its present condition; (iii) an active program to locate a buyer and a plan to sell the business have been initiated; (iv) the sale of the business is probable within one year; (v) the business is being actively marketed for sale at a reasonable price relative to its fair value; and (vi) it is unlikely that the plan to sell will be withdrawn or that significant changes to the plan will be made.

In determining the fair value of the assets less costs to sell, the Company considers factors including current sales prices for comparable assets, discounted cash flow projections, third party valuation and any indicative offers. The Company's assumptions about fair value require significant judgment because the current market is highly sensitive to changes in economic conditions. The Company estimates the fair values of assets held for sale based on current market conditions and assumptions made by management, which may differ from actual results and may result in impairments if market conditions deteriorate.

Any impairment loss on the initial classification and subsequent measurement is recognized as an expense. Any subsequent increase in fair value less costs to sell (not exceeding the accumulated impairment loss that has been previously recognized) is recognized in the income statement.

When assets are classified as held for sale, the Company does not record any depreciation and amortization for the respective property, plant and equipment and intangibles.

(n) Recently issued accounting pronouncements

The authoritative bodies release standards and guidance which are assessed by management for impact on the Company's consolidated financial statements.

The following recently released accounting standard has not yet been adopted by the Company:

In November 2021, the FASB issued ASU No. 2021-10, "Government Assistance." This ASU improves financial reporting by requiring disclosures that increase the transparency of transactions with governments. The ASU is effective for the Company for annual periods, beginning December 15, 2021. Early adoption is permitted. The Company is in the process of assessing the impact of this ASU on its consolidated results of operations, cash flows, financial position and disclosures.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

3. Business acquisitions

(a) Hoodoo Digital, LLC

On December 31, 2021, the Company acquired 100% of the outstanding equity/limited liability company interests in Hoodoo Digital, LLC, a Utah limited liability company, for total purchase consideration of \$66,722. This amount represents cash consideration of \$64,439, net of cash acquired of \$2,283. The total purchase consideration paid by the Company to the sellers was \$67,695, resulting in a recoverable of \$973 on the closing date, which was subsequently recovered. The Company has made measurement period adjustments of \$1,688 related to taxes, and this amount was outstanding as of September 30, 2022. The Company is evaluating adjustments related to certain income and other taxes, which, when determined, may result in the recognition of additional assets or liabilities as of the acquisition date. The measurement period will not exceed one year from the acquisition date. This acquisition furthers the Company's strategy to fuse experience and process innovation to help clients drive end-to-end digital transformation. Hoodoo Digital's expertise with Adobe Experience Manager and other Adobe applications expands the Company's existing capabilities to provide clients with an end-to-end solution that integrates digital content, e-commerce, data analytics, and marketing operations.

In connection with this acquisition, the Company recorded \$16,200 in customer-related intangibles and \$2,400 in marketing-related intangibles which have a weighted average amortization period of five years. Goodwill arising from the acquisition amounting to \$46,033 has been allocated using a relative fair value allocation method to each of the Company's reporting segments as follows: to the Financial Services segment in the amount of \$4,338, to the Consumer and Healthcare segment in the amount of \$7,321 and to the High Tech and Manufacturing segment in the amount of \$34,374.

Goodwill arising from this acquisition is deductible for income tax purposes. The goodwill represents primarily the acquired capabilities and other benefits expected to result from combining the acquired operations with the Company's existing operations.

Acquisition-related costs of \$1,177 have been included in selling, general and administrative expenses as incurred. In connection with the acquisition, the Company also acquired certain assets with a value of \$5,629 and assumed certain liabilities amounting to \$1,852. The agreement with the sellers provides a full indemnity to the Company for all pre-closing income and non-income tax liabilities up to a maximum of the purchase consideration, including interest and penalties thereon. The Company would not be financially or materially affected by any liabilities that may arise from such exposures.

Accordingly, the Company recognized an indemnification asset of \$278 based on the information that was available at the date of the acquisition, which is included in the assets taken over by the Company. The results of operations of the acquired business and the fair value of the acquired assets and assumed liabilities are included in the Company's consolidated financial statements with effect from the date of the acquisition.

(b) Enquero Inc

On December 31, 2020, the Company acquired 100% of the outstanding equity interests in Enquero Inc, a California corporation, and certain affiliated entities in India, the Netherlands and Canada (collectively referred to as "Enquero") for total purchase consideration of \$148,797. This amount represents cash consideration of \$137,166, net of cash acquired of \$11,631. The total purchase consideration paid by the Company to the sellers on the closing date was \$141,938. No portion of the purchase consideration is outstanding as of September 30, 2022. This acquisition increased the scale and depth of the Company's data and analytics capabilities and enhanced the Company's ability to accelerate the digital transformation journeys of its clients through cloud technologies and advanced data analytics.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

3. Business acquisitions (Continued)

In connection with this acquisition, the Company recorded \$49,000 in customer-related intangibles, \$9,500 in marketing-related intangibles and \$1,400 in technology-related intangibles, which have a weighted average amortization period of four years. Goodwill arising from the acquisition amounting to \$87,874 has been allocated using a relative fair value allocation method to each of the Company's reporting segments as follows: to the Financial Services segment in the amount of \$2,594, to the Consumer and Healthcare segment in the amount of \$22,548 and to the High Tech and Manufacturing segment in the amount of \$62,732. The goodwill arising from this acquisition is not deductible for income tax purposes. The goodwill represents primarily the acquired capabilities and other benefits expected to result from combining the acquired operations with the Company's existing operations.

Acquisition-related costs of \$1,590 have been included in selling, general and administrative expenses as incurred. In connection with the transaction, the Company also acquired certain assets with a value of \$32,879, assumed certain liabilities amounting to \$17,232 and recognized a net deferred tax liability of \$14,343. The agreement with the sellers provides a full indemnity to the Company for all pre-closing income and non-income tax liabilities up to a maximum of the purchase consideration, including interest and penalties thereon. The Company would not be financially or materially affected by any liabilities that may arise from such exposures.

Accordingly, the Company recognized an indemnification asset of \$5,968 based on the information that was available at the date of the acquisition, which is included in the assets taken over by the Company. The results of operations of the acquired business and the fair value of the acquired assets and assumed liabilities are included in the Company's consolidated financial statements with effect from the date of the acquisition.

(c) SomethingDigital.Com LLC

On October 5, 2020, the Company acquired 100% of the outstanding equity/limited liability company interests in SomethingDigital.Com LLC, a New York limited liability company, for total purchase consideration of \$57,451. This amount represents cash consideration of \$56,073, net of cash acquired of \$1,378. The total purchase consideration paid by the Company to the sellers on the closing date was \$57,704, resulting in a recoverable of \$253. No portion of the purchase consideration is outstanding as of September 30, 2022.

This acquisition supported the Company's strategy to integrate experience and process innovation to help clients on their digital transformation journeys and expanded on the Company's existing experience capabilities to support end-to-end digital commerce solutions, both business-to-business and business-to-consumer. Additionally, this acquisition expanded the Company's capabilities into Magento Commerce, which powers Adobe Commerce Cloud, and Shopify Plus, a cloud-based e-commerce platform for high volume merchants.

In connection with this acquisition, the Company recorded \$11,900 in customer-related intangibles and \$3,500 in marketing-related intangibles which have a weighted average amortization period of four years. Goodwill arising from the acquisition amounting to \$36,926 has been allocated using a relative fair value allocation method to two of the Company's reporting segments as follows: to the Consumer and Healthcare segment in the amount of \$30,373 and to the High Tech and Manufacturing segment in the amount of \$6,553. Of the total goodwill arising from this acquisition, \$35,084 is deductible for income tax purposes.

The goodwill represents primarily the acquired capabilities and other benefits expected to result from combining the acquired operations with those of the Company's existing operations.

Acquisition-related costs of \$1,060 have been included in selling, general and administrative expenses as incurred. In connection with the transaction, the Company also acquired certain assets with a value of \$9,538, assumed certain liabilities amounting to \$4,494 and recognized a net deferred tax asset of \$81. The results of operations of the acquired business and the fair value of the acquired assets and assumed liabilities are included in the Company's consolidated financial statements with effect from the date of the acquisition.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

3. Business acquisitions (Continued)

(d) Rightpoint Consulting, LLC

On November 12, 2019, the Company acquired 100% of the outstanding equity/limited liability company interests in Rightpoint Consulting, LLC, an Illinois limited liability company, and certain affiliated entities in the United States and India (collectively referred to as "Rightpoint") for total purchase consideration of \$270,669. This amount includes cash consideration of \$268,170, net of cash acquired of \$2,499. The total purchase consideration paid by the Company to the sellers on the closing date was \$248,470, resulting in a payable of \$22,199. \$2,517 of the total purchase consideration remains payable as of September 30, 2022. This acquisition expanded the Company's capabilities in improving customer experience.

The securities purchase agreement between the Company and the selling equity holders of Rightpoint provided certain of the selling equity holders the option to elect to either (a) receive 100% consideration in cash at the closing date for their limited liability company interests and vested options or (b) "roll over" and retain 25% of their Rightpoint limited liability company interests and vested options for a three-year rollover period and receive cash consideration at closing for the remaining 75% of their Rightpoint limited liability company interests and vested options. Certain selling equity holders elected to receive deferred, variable earn-out consideration with an estimated value of \$21,500 over the rollover period of three years.

The amount of deferred earn-out consideration ultimately payable by the Company to the selling equity holders of Rightpoint will be based on the future revenue multiple of the acquired business. Additionally, under the purchase agreement the selling equity holders are obligated to sell their rollover interests to the Company. Accordingly, the Company has obtained control over 100% of the outstanding equity/limited liability company interests of Rightpoint as of November 12, 2019. See Note 5, "Fair value measurements," for additional details.

In connection with this acquisition, the Company recorded \$46,000 in customer-related intangibles and \$29,000 in marketing-related intangibles which have a weighted average amortization period of five years. Goodwill arising from the acquisition amounting to \$177,181 has been allocated using a relative fair value allocation method to each of the Company's reporting segments as follows: to the Financial Services segment in the amount of \$16,983, to the Consumer and Healthcare segment in the amount of \$42,993 and to the High Tech and Manufacturing segment in the amount of \$117,205. Of the total goodwill arising from this acquisition, \$91,929 is deductible for income tax purposes. The goodwill represents primarily the acquired capabilities and other benefits expected to result from combining the acquired operations with those of the Company.

Acquisition-related costs of \$7,385 have been included in selling, general and administrative expenses as incurred. In connection with the transaction, the Company also acquired certain assets with a value of \$39,140, assumed certain liabilities amounting to \$22,295 and recognized a net deferred tax liability of \$1,643. The results of operations of the acquired business and the fair value of the acquired assets and assumed liabilities are included in the Company's consolidated financial statements with effect from the date of the acquisition.

4. Accounts receivable, net of allowance for credit losses

The following table provides details of the Company's allowance for credit losses on accounts receivable:

	Year ended December 31, 2021	Nine months ended September 30, 2022
Opening balance as of January 1	\$ 27,707	\$ 24,329
Additions charged/reversal released to cost and expense	910	1,558
Deductions/effect of exchange rate fluctuations	(4,288)	(5,450)
Closing balance	\$ 24,329	\$ 20,437

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

4. Accounts receivable, net of allowance for credit losses (Continued)

Accounts receivable were \$912,071 and \$1,014,687, and allowances for credit losses were \$24,329 and \$20,437, resulting in net accounts receivable balances of \$887,742 and \$994,250 as of December 31, 2021 and September 30, 2022, respectively. As of September 30, 2022, the Company reclassified accounts receivable amounting to \$4,653 as assets held for sale. See Note 8 for additional information.

In addition, deferred billings were \$48,071 and \$59,103 and allowances for credit losses on deferred billings were \$3,711 and \$3,198, resulting in net deferred billings balances of \$44,360 and \$55,905 as of December 31, 2021 and September 30, 2022, respectively.

During the nine months ended September 30, 2021 and 2022, the Company recorded a release of \$541 and \$513, respectively, to cost and expense on account of credit losses on deferred billings. Deferred billings, net of related allowances for credit losses, are included under "other assets" in the Company's consolidated balance sheet as of December 31, 2021 and September 30, 2022.

The Company has a revolving accounts receivable-based facility of \$100,000 permitting it to sell accounts receivable to banks on a non-recourse basis in the ordinary course of business. The aggregate maximum capacity utilized by the Company at any time during the period ended December 31, 2021 and September 30, 2022 was \$7,053 and \$67,439, respectively. The principal amount outstanding against this facility as of December 31, 2021 and September 30, 2022 was \$0 and \$27,302, respectively. The cost of factoring such accounts receivable during the three and nine months ended September 30, 2021 and 2022 was \$29 and \$146, respectively, and \$40 and \$304, respectively. Gains or losses on the sales are recorded at the time of transfer of the accounts receivable and are included under "interest income (expense), net" in the Company's consolidated statements of income.

5. Fair value measurements

The Company measures certain financial assets and liabilities, including derivative instruments, at fair value on a recurring basis. The fair value measurements of these financial assets and liabilities were determined using the following inputs as of December 31, 2021 and September 30, 2022:

As of December 31, 2021					
Fair Value Measurements at Reporting Date Using					
	Total	Quoted Prices in Active Markets for Identical Assets	Significant Other Observable Inputs	Significant Other Unobservable Inputs	
		(Level 1)	(Level 2)	(Level 3)	
Assets					
Derivative instruments (Note a, c)	\$ 34,070	\$ —	\$ 34,070	\$ —	—
Deferred compensation plan assets (Note a, e)	38,584	—	—	—	38,584
Total	\$ 72,654	\$ —	\$ 34,070	\$ —	38,584
Liabilities					
Earn-out consideration (Note b, d)	\$ 5,406	\$ —	\$ —	\$ —	5,406
Derivative instruments (Note b, c)	15,254	—	15,254	—	—
Deferred compensation plan liability (Note b, f)	38,007	—	—	—	38,007
Total	\$ 58,667	\$ —	\$ 15,254	\$ —	43,413

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

5. Fair value measurements (Continued)

As of September 30, 2022				
Fair Value Measurements at Reporting Date Using				
	Total	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Other Unobservable Inputs (Level 3)
Assets				
Derivative instruments (Note a, c)	\$ 35,625	\$ —	\$ 35,625	\$ —
Deferred compensation plan assets (Note a, e)	37,183	—	—	37,183
Total	\$ 72,808	\$ —	\$ 35,625	\$ 37,183
Liabilities				
Earn-out consideration (Note b, d)	\$ 2,517	\$ —	\$ —	\$ 2,517
Derivative instruments (Note b, c)	59,199	—	59,199	—
Deferred compensation plan liability (Note b, f)	36,583	—	—	36,583
Total	\$ 98,299	\$ —	\$ 59,199	\$ 39,100

- (a) Derivative assets are included in “prepaid expenses and other current assets” and “other assets.” Deferred compensation plan assets are included in “other assets” in the consolidated balance sheets.
- (b) Included in “accrued expenses and other current liabilities” and “other liabilities” in the consolidated balance sheets.
- (c) The Company values its derivative instruments based on market observable inputs, including both forward and spot prices for the relevant currencies and interest rate indices for relevant interest rates. The quotes are taken from an independent market database.
- (d) The fair value of earn-out consideration, calculated as the present value of expected future payments to be made to the sellers of acquired businesses, was derived by estimating the future financial performance of the acquired businesses using the earn-out formula and performance targets specified in each purchase agreement and adjusting the result to reflect the Company’s estimate of the likelihood of achievement of such targets. Given the significance of the unobservable inputs, the valuations are classified in level 3 of the fair value hierarchy.
- (e) Deferred compensation plan assets consist of life insurance policies held under a Rabbi Trust. Assets held in the Rabbi Trust are valued based on the cash surrender value of the insurance contract, which is determined based on the fair value of the underlying assets included in the insurance portfolio and are therefore classified within level 3 of the fair value hierarchy.
- (f) The fair value of the deferred compensation plan liability is derived based on the fair value of the underlying assets in the insurance policies and is therefore classified within level 3 of the fair value hierarchy.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

5. Fair value measurements (Continued)

The following table provides a roll-forward of the fair value of earn-out consideration categorized as level 3 in the fair value hierarchy for the three and nine months ended September 30, 2021 and 2022:

	Three months ended September 30,		Nine months ended September 30,	
	2021	2022	2021	2022
Opening balance	\$ 5,716	\$ 5,406	\$ 8,272	\$ 5,406
Payments made on earn-out consideration (Note a)	—	(2,437)	(2,556)	(2,437)
Change in fair value of earn-out consideration (Note b)	\$ —	\$ (452)	\$ —	\$ (452)
Others (Note c)	440	—	440	—
Closing balance	\$ 6,156	\$ 2,517	\$ 6,156	\$ 2,517

- (a) Includes an interest payment on earn-out consideration in excess of the acquisition date fair value, which is included in “cash flows from operating activities,” amounting to \$440 for the three and nine months ended September 30, 2021 and \$0 for the three and nine months ended September 30, 2022.
- (b) Changes in the fair value of earn-out consideration are reported in “other operating (income) expense, net” in the consolidated statements of income.
- (c) “Others” is comprised of interest expense included in “interest income (expense), net” and the impact of changes in foreign exchange reported in “foreign exchange gains (losses), net” in the consolidated statements of income. This also includes a cumulative translation adjustment reported as a component of “other comprehensive income (loss).”

The following table provides a roll-forward of the fair value of deferred compensation plan assets categorized as level 3 in the fair value hierarchy for the three and nine months ended September 30, 2021 and 2022:

	Three months ended September 30,		Nine months ended September 30,	
	2021	2022	2021	2022
Opening balance	\$ 35,533	\$ 38,422	\$ 26,832	\$ 38,584
Additions (net of redemption)	857	725	6,816	8,610
Change in fair value of deferred compensation plan assets (Note a)	(84)	(1,964)	2,658	(10,011)
Closing balance	\$ 36,306	\$ 37,183	\$ 36,306	\$ 37,183

- (a) Changes in the fair value of plan assets are reported in “other income (expense), net” in the consolidated statements of income.

The following table provides a roll-forward of the fair value of deferred compensation liabilities categorized as level 3 in the fair value hierarchy for the three and nine months ended September 30, 2021 and 2022:

	Three months ended September 30,		Nine months ended September 30,	
	2021	2022	2021	2022
Opening balance	\$ 35,034	\$ 37,833	\$ 26,390	\$ 38,007
Additions (net of redemption)	840	727	6,799	8,611
Change in fair value of deferred compensation plan liabilities (Note a)	(159)	(1,977)	2,526	(10,035)
Closing balance	\$ 35,715	\$ 36,583	\$ 35,715	\$ 36,583

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

5. Fair value measurements (Continued)

(a) Changes in the fair value of deferred compensation plan liabilities are reported in “selling, general and administrative expenses” in the consolidated statements of income.

6. Derivative financial instruments

The Company is exposed to the risk of rate fluctuations on its foreign currency assets and liabilities and on foreign currency denominated forecasted cash flows and interest rates. The Company has established risk management policies, including the use of derivative financial instruments to hedge foreign currency assets and liabilities, foreign currency denominated forecasted cash flows and interest rate risk. These derivative financial instruments consist of deliverable and non-deliverable forward foreign exchange contracts, treasury rate locks and interest rate swaps. The Company enters into these contracts with counterparties that are banks or other financial institutions, and the Company considers the risk of non-performance by such counterparties not to be material. The forward foreign exchange contracts and interest rate swaps mature during a period of up to 51 months and the forecasted transactions are expected to occur during the same period.

The following table presents the aggregate notional principal amounts of outstanding derivative financial instruments together with the related balance sheet exposure:

	Notional principal amounts (Note a)		Balance sheet exposure asset (liability) (Note b)	
	As of December 31, 2021	As of September 30, 2022	As of December 31, 2021	As of September 30, 2022
Foreign exchange forward contracts denominated in:				
United States Dollars (sell) Indian Rupees (buy)	\$ 1,348,600	\$ 1,617,900	\$ 26,247	\$ (42,942)
United States Dollars (sell) Mexican Peso (buy)	23,750	31,000	140	484
United States Dollars (sell) Philippines Peso (buy)	75,600	78,600	(2,215)	(6,548)
Euro (sell) United States Dollars (buy)	120,994	104,785	2,634	12,786
Singapore Dollars (buy) United States Dollars (sell)	3,655	48,736	65	(1,140)
Euro (sell) Romanian Leu (buy)	47,506	42,726	(233)	380
Japanese Yen (sell) Chinese Renminbi (buy)	10,440	3,124	202	394
United States Dollars (sell) Chinese Renminbi (buy)	45,000	11,250	120	(872)
Pound Sterling (sell) United States Dollars (buy)	49,031	29,917	545	4,291
United States Dollars (sell) Hungarian Font (buy)	39,000	22,500	(2,174)	(3,238)
Hungarian Font (Sell) Euro (buy)	2,828	—	(17)	—
Australian Dollars (sell) Indian Rupees (buy)	97,053	74,719	1,234	4,699
USD (Sell) Polish Zloty (buy)	—	24,000	—	(2,515)
Japanese Yen (sell) US Dollar (buy)	—	10,000	—	808
Israel Shekel (sell) US Dollar (buy)	—	3,000	—	107
South African Rand (sell) US Dollar (buy)	—	15,000	—	764
Interest rate swaps (floating to fixed)	460,135	439,220	(7,732)	8,968
			\$ 18,816	\$ (23,574)

(a) Notional amounts are key elements of derivative financial instrument agreements but do not represent the amount exchanged by counterparties and do not measure the Company’s exposure to credit, foreign exchange, interest rate or market risks. However, the amounts exchanged are based on the notional amounts and other provisions of the underlying derivative financial instrument agreements. Notional amounts are denominated in U.S. dollars.

(b) Balance sheet exposure is denominated in U.S. dollars and denotes the mark-to-market impact of the derivative financial instruments on the reporting date.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

6. Derivative financial instruments (Continued)

FASB guidance on derivatives and hedging requires companies to recognize all derivative instruments as either assets or liabilities at fair value in the balance sheet. In accordance with the FASB guidance on derivatives and hedging, the Company designates foreign exchange forward contracts, interest rate swaps and treasury rate locks as cash flow hedges. Foreign exchange forward contracts are entered into to cover the effects of future exchange rate variability on forecasted revenues and purchases of services, and interest rate swaps and treasury rate locks are entered into to cover interest rate fluctuation risk. In addition to this program, the Company uses derivative instruments that are not accounted for as hedges under the FASB guidance in order to hedge foreign exchange risks related to balance sheet items, such as receivables and intercompany borrowings, that are denominated in currencies other than the Company's underlying functional currency.

The fair value of the Company's derivative instruments and their location in the Company's financial statements are summarized in the table below:

	Cash flow hedges		Non-designated	
	As of December 31, 2021	As of September 30, 2022	As of December 31, 2021	As of September 30, 2022
Assets				
Prepaid expenses and other current assets	\$ 16,064	\$ 27,363	\$ 3,130	\$ 2,727
Other assets	\$ 14,876	\$ 5,524	\$ —	\$ 11
Liabilities				
Accrued expenses and other current liabilities	\$ 11,408	\$ 32,150	\$ 1,090	\$ 16,971
Other liabilities	\$ 2,756	\$ 10,078	\$ —	\$ —

Cash flow hedges

For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain (loss) on the derivative instrument is reported as a component of other comprehensive income (loss) and reclassified into earnings in the same period or periods during which the hedged transaction is recognized in the consolidated statements of income. Gains (losses) on the derivatives, representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness, are recognized in earnings as incurred.

The Company executed a treasury rate lock agreement for \$350,000 in connection with future interest payments to be made on its senior notes issued by Genpact Luxembourg S.à r.l. ("Genpact Luxembourg") and Genpact USA, Inc. ("Genpact USA"), both wholly-owned subsidiaries of the Company, in March 2021 (the "2021 Senior Notes"), and the treasury rate lock was designated as a cash flow hedge. The treasury rate lock agreement was terminated on March 23, 2021 and a deferred gain was recorded in accumulated other comprehensive income and is being amortized to interest expense over the life of the 2021 Senior Notes. The remaining gain to be amortized related to the treasury rate lock agreement as of September 30, 2022 was \$571.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

6. Derivative financial instruments (Continued)

In connection with cash flow hedges, the gains (losses) recorded as a component of other comprehensive income (loss) ("OCI"), and the related tax effects are summarized below:

	Three months ended September 30,					
	2021			2022		
	Before tax Amount	Tax (Expense) or Benefit	Net of tax Amount	Before tax Amount	Tax (Expense) or Benefit	Net of tax Amount
Opening balance	\$ (7,883)	\$ 1,355	\$ (6,528)	\$ 8,284	\$ (3,078)	\$ 5,206
Net gains (losses) reclassified into statement of income on completion of hedged transactions	2,443	(526)	1,917	(2,274)	(153)	(2,427)
Changes in fair value of effective portion of outstanding derivatives, net	11,984	(2,278)	9,706	(19,328)	2,703	(16,625)
Gain (loss) on cash flow hedging derivatives, net	9,541	(1,752)	7,789	(17,054)	2,856	(14,198)
Closing balance	\$ 1,658	\$ (397)	\$ 1,261	\$ (8,770)	\$ (222)	\$ (8,992)

	Nine months ended September 30,					
	2021			2022		
	Before tax Amount	Tax (Expense) or Benefit	Net of tax Amount	Before tax Amount	Tax (Expense) or Benefit	Net of tax Amount
Opening balance	\$ (10,921)	\$ 1,861	\$ (9,060)	\$ 17,468	\$ (3,404)	\$ 14,064
Net gains (losses) reclassified into statement of income on completion of hedged transactions	6,361	(1,463)	4,898	(2,551)	(423)	(2,974)
Changes in fair value of effective portion of outstanding derivatives, net	18,940	(3,721)	15,219	(28,789)	2,759	(26,030)
Gain (loss) on cash flow hedging derivatives, net	12,579	(2,258)	10,321	(26,238)	3,182	(23,056)
Closing balance	\$ 1,658	\$ (397)	\$ 1,261	\$ (8,770)	\$ (222)	\$ (8,992)

The gains or losses recognized in other comprehensive income (loss) and their effects on financial performance are summarized below:

Derivatives in Cash Flow Hedging Relationships	Amount of Gain (Loss) recognized in OCI on Derivatives (Effective Portion)				Location of Gain (Loss) reclassified from OCI into Statement of Income (Effective Portion)	Amount of Gain (Loss) reclassified from OCI into Statement of Income (Effective Portion)			
	Three months ended September 30,		Nine months ended September 30,			Three months ended September 30,		Nine months ended September 30,	
	2021	2022	2021	2022		2021	2022	2021	2022
Forward foreign exchange contracts	\$ 12,175	\$ (22,264)	\$ 17,457	\$ (42,948)	Revenue	\$ 416	\$ 1,089	\$ 515	\$ 2,269
Interest rate swaps	\$ (191)	\$ 2,936	\$ 667	\$ 14,159	Cost of revenue	3,160	(3,334)	9,288	(2,284)
Treasury rate lock	\$ —	\$ —	\$ 816	\$ —	Selling, general and administrative expenses	849	(566)	2,513	(116)
					Interest expense	(1,982)	537	(5,955)	(2,420)
	\$ 11,984	\$ (19,328)	\$ 18,940	\$ (28,789)		\$ 2,443	\$ (2,274)	\$ 6,361	\$ (2,551)

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

6. Derivative financial instruments (Continued)

There were no gains (losses) recognized in the statement of income on the ineffective portion of derivatives and excluded from effectiveness testing for the three and nine months ended September 30, 2021 and 2022, respectively.

Non-designated Hedges

Derivatives not designated as hedging instruments	Location of Gain (Loss) recognized in Statement of Income on Derivatives	Amount of Gain (Loss) recognized in Statement of Income on Derivatives			
		Three months ended September 30,		Nine months ended September 30,	
		2021	2022	2021	2022
Forward foreign exchange contracts (Note a)	Foreign exchange gains (losses), net	\$ 3,938	\$ (12,705)	\$ 8,775	\$ (29,649)
		<u>\$ 3,938</u>	<u>\$ (12,705)</u>	<u>\$ 8,775</u>	<u>\$ (29,649)</u>

(a) These forward foreign exchange contracts were entered into to hedge fluctuations in foreign exchange rates for recognized balance sheet items such as receivables and intercompany borrowings, and were not originally designated as hedges under FASB guidance on derivatives and hedging. Realized gains (losses) and changes in the fair value of these derivatives are recorded in foreign exchange gains (losses), net in the consolidated statements of income.

In connection with the COVID-19 pandemic, the Company has reevaluated its hedging arrangements. The Company has considered the effect of changes, if any, in both counterparty credit risk and the Company's own non-performance risk while assessing hedge effectiveness and measuring hedge ineffectiveness. The Company believes that its hedges continue to be effective after taking into account the expected impact of the COVID-19 pandemic on the Company's hedged transactions.

7. Prepaid expenses and other current assets

Prepaid expenses and other current assets consist of the following:

	As of December 31, 2021	As of September 30, 2022
Advance income and non-income taxes	\$ 28,075	\$ 110,908
Contract asset (Note 20)	8,506	14,506
Prepaid expenses	38,528	44,341
Derivative instruments	19,194	30,090
Employee advances	2,797	3,199
Deposits	5,839	4,970
Advances to suppliers	804	797
Others	30,698	21,014
	<u>\$ 134,441</u>	<u>\$ 229,825</u>

As of September 30, 2022, the Company reclassified certain prepaid expenses and other current assets amounting to \$1,200 to assets held for sale. See Note 8 for additional information.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

8. Assets and liabilities held for sale

The Company is taking actions to realign its portfolio to focus on emerging solutions where it sees the greatest opportunities for growth, and deprioritizing assets that no longer fit with its long-term strategy. Pursuant to a plan approved by management in the second quarter of 2022, the Company is in the process of divesting a business that comprises part of the Company's Consumer and Healthcare segment.

It is the Company's intention to complete the sale of this business within the twelve months following the end of the second quarter of 2022. Accordingly, the Company classified this business as held for sale during the second quarter of 2022.

As a result, the Company classified \$37,047 of assets (before recording an impairment charge of \$21,426) and \$8,410 of liabilities as held for sale as of September 30, 2022.

During the three and nine months ended September 30, 2022, the Company recorded a non-cash impairment charge of \$21,426 to adjust the carrying amount of assets to their fair value. Of the total impairment charge of \$21,426, \$19,801 pertains to intangible assets and \$1,625 pertains to goodwill. The impairment loss has been recorded in "other operating (income) expense, net" in the consolidated statement of income. See Note 10 for additional information.

The components of assets and liabilities of the business classified as held for sale (after recording an impairment charge) in the consolidated balance sheet consist of the following:

	As of September 30, 2022	
Accounts receivable	\$	4,653
Prepaid expense and other current assets		1,200
Property, plant and equipment, net		18
Intangible assets, net		6,370
Contract cost assets		1,417
Other assets		1,963
Assets of business held for sale	\$	15,621
Accounts payable	\$	410
Accrued expenses and other current liabilities		7,141
Other liabilities		859
Liabilities of business held for sale	\$	8,410

9. Property, plant and equipment, net

The following table provides the gross and net amount of property, plant and equipment:

	As of December 31, 2021		As of September 30, 2022	
Property, plant and equipment, gross	\$	818,452	\$	754,762
Less: Accumulated depreciation and amortization		(603,363)		(574,383)
Property, plant and equipment, net	\$	215,089	\$	180,379

Depreciation expense on property, plant and equipment for the nine months ended September 30, 2021 and 2022 was \$46,305 and \$42,102, respectively, and for the three months ended September 30, 2021 and 2022 was \$14,131 and \$13,442, respectively. Computer software amortization for the nine months ended September 30, 2021 and 2022 was \$4,469 and \$3,874, respectively, and for the three months ended September 30, 2021 and 2022 was \$1,461 and \$1,192, respectively. The Company recorded a write-down to certain property, plant and equipment during the three and nine months ended September 30, 2021 and 2022, as described in Note 10.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

9. Property, plant and equipment, net (Continued)

As of September 30, 2022, the Company reclassified certain property, plant and equipment with a gross carrying value and accumulated depreciation of \$368 and \$350, respectively, to assets held for sale. See Note 8 for additional information.

10. Goodwill and intangible assets

The following table presents the changes in goodwill for the year ended December 31, 2021 and nine months ended September 30, 2022:

	For the year ended December 31, 2021	For the nine months ended September 30, 2022
Opening balance	1,695,688	1,731,027
Goodwill relating to acquisitions consummated during the period	44,216	—
Impact of measurement period adjustments	1,205	1,817
Reclassified as held for sale	—	(1,625)
Effect of exchange rate fluctuations	(10,082)	(50,287)
Closing balance	1,731,027	1,680,932

The following table presents the changes in goodwill by reporting unit for the year ended December 31, 2021:

	Financial Services	Consumer and Healthcare	High Tech and Manufacturing	Total
Opening balance	420,172	607,574	667,942	1,695,688
Goodwill relating to acquisitions consummated during the period	4,167	7,032	33,017	44,216
Impact of measurement period adjustments	35	309	861	1,205
Effect of exchange rate fluctuations	(3,117)	(3,795)	(3,170)	(10,082)
Closing balance	421,257	611,120	698,650	1,731,027

The following table presents the changes in goodwill by reporting unit for the nine months ended September 30, 2022:

	Financial Services	Consumer and Healthcare	High Tech and Manufacturing	Total
Opening balance	421,257	611,120	698,650	1,731,027
Impact of measurement period adjustments	171	289	1,357	1,817
Reclassified as held for sale	—	(1,625)	—	(1,625)
Effect of exchange rate fluctuations	(13,796)	(18,143)	(18,348)	(50,287)
Closing balance	407,632	591,641	681,659	1,680,932

As of September 30, 2022, the Company reclassified goodwill (before impairment) amounting to \$1,625 attributable to its Consumer and Healthcare segment as assets held for sale. See Note 8 for additional information.

The total amount of goodwill deductible for tax purposes was \$326,795 and \$305,244 (including goodwill reclassified as held for sale) as of December 31, 2021 and September 30, 2022, respectively.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

10. Goodwill and intangible assets (Continued)

The Company's intangible assets are as follows:

	As of December 31, 2021			As of September 30, 2022		
	Gross carrying amount	Accumulated amortization & Impairment	Net	Gross carrying amount	Accumulated amortization & Impairment	Net
Customer-related intangible assets	\$ 489,974	\$ 394,688	\$ 95,286	\$ 471,875	\$ 402,357	\$ 69,518
Marketing-related intangible assets	98,870	76,663	22,207	97,710	81,215	16,495
Technology-related intangible assets	171,772	119,630	52,142	125,497	110,284	15,213
	<u>\$ 760,616</u>	<u>\$ 590,981</u>	<u>\$ 169,635</u>	<u>\$ 695,082</u>	<u>\$ 593,856</u>	<u>\$ 101,226</u>

As of September 30, 2022, the Company reclassified certain intangible assets (before impairment) with a gross carrying value and accumulated amortization of \$50,432 and \$24,261, respectively, to assets held for sale. See Note 8 for additional information.

Amortization expenses for intangible assets acquired as part of a business combination and disclosed in the consolidated statements of income under amortization of acquired intangible assets for the nine months ended September 30, 2021 and 2022 were \$44,624 and \$32,805, respectively, and for the three months ended September 30, 2021 and 2022 were \$13,898 and \$10,604, respectively.

Amortization expenses for internally-developed and other intangible assets disclosed in the consolidated statements of income under cost of revenue and selling, general and administrative expenses for the nine months ended September 30, 2021 and 2022 were \$18,841 and \$12,264, respectively, and for the three months ended September 30, 2021 and 2022 were \$6,919 and \$2,595, respectively.

During the three and nine months ended September 30, 2021 and 2022, the Company tested for recoverability certain customer-related and technology-related intangible assets, including those under development, and certain property, plant and equipment, as a result of changes in market trends and the Company's investment strategy, including the Company's decisions to cease certain service offerings. Based on the results of this testing, the Company determined that the carrying values of the assets tested were not recoverable, and the Company recorded complete write-downs of the carrying values of these assets amounting to \$915 and \$1,377 for the nine months ended September 30, 2021 and 2022, respectively, and zero for the three months ended September 30, 2021 and 2022, respectively. These write-downs have been recorded in "other operating (income) expense, net" in the consolidated statement of income.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

10. Goodwill and intangible assets (Continued)

The summary below presents the impairment charges (on intangibles and goodwill) and write-downs (on property, plant and equipment) recorded for various categories of assets during the three and nine months ended September 30, 2021 and September 30, 2022:

	Three months ended September 30,		Nine months ended September 30,	
	2021	2022	2021	2022
Technology related intangibles	\$ —	\$ 19,116	\$ 205	\$ 19,116
Customer related intangibles	—	685	—	685
Goodwill	—	1,625	—	1,625
Total intangibles and goodwill	\$ —	\$ 21,426	\$ 205	\$ 21,426
Property, plant and equipment	\$ —	—	\$ 710	\$ 1,377
Total property, plant and equipment	\$ —	\$ —	\$ 710	\$ 1,377
Total impairment and write-down	\$ —	\$ 21,426	\$ 915	\$ 22,803

11. Short-term borrowings

The Company has the following borrowing facilities:

- a. Fund-based and non-fund-based credit facilities with banks, which are available for operational requirements in the form of overdrafts, letters of credit, guarantees and short-term loans. As of December 31, 2021 and September 30, 2022, the limits available were \$24,727 and \$22,869, respectively, of which \$5,848 and \$5,025, respectively, was utilized, constituting non-funded drawdown.
- b. A fund-based and non-fund based revolving credit facility of \$500,000, which the Company obtained through an amendment of its existing credit agreement on August 9, 2018. The amended credit facility expires on August 8, 2023. The Company is in the process of refinancing its credit facility, and is currently in negotiation with various financial institutions, and the refinancing is expected to close in the fourth quarter of 2022. The funded drawdown amount under the Company's revolving facilities bore interest at a rate equal to LIBOR plus a margin of 1.375% as of December 31, 2021 and September 30, 2022. The unutilized amount on the revolving facilities bore a commitment fee of 0.20% as of December 31, 2021 and September 30, 2022. As of December 31, 2021 and September 30, 2022, a total of \$2,017 and \$202,658, respectively, was utilized, of which \$0 and \$200,000, respectively, constituted funded drawdown and \$2,017 and \$2,658, respectively, constituted non-funded drawdown. The Company's amended credit agreement contains certain customary covenants, including a maximum leverage covenant and a minimum interest coverage ratio. During the period ended December 31, 2021 and September 30, 2022, the Company was in compliance with the financial covenants of the credit agreement.

12. Long-term debt

Borrowings under the Company's credit facility, which was amended in August 2018, bear interest at a rate equal to, at the election of the Company, either LIBOR plus an applicable margin equal to 1.375% per annum or a base rate plus an applicable margin equal to 0.375% per annum, in each case subject to adjustment based on the Company's debt ratings provided by Standard & Poor's Rating Services and Moody's Investors Service, Inc. Based on the Company's election and current credit rating, the applicable interest rate is equal to LIBOR plus 1.375% per annum. The amended credit agreement restricts certain payments, including dividend payments, if there is an event of default under the amended credit agreement or if the Company is not, or after making the payment would not be, in compliance with certain financial covenants contained in the amended credit agreement. These covenants require the Company to maintain a net debt to EBITDA leverage ratio of below 3x and an interest coverage ratio of more than 3x. During the period ended September 30, 2022, the Company was in compliance with the terms of the credit agreement, including all of the financial covenants therein.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

12. Long-term debt (Continued)

The Company's retained earnings are not subject to any restrictions on availability to make dividend payments to shareholders, subject to compliance with the financial covenants described above that are contained in the amended credit agreement.

As of December 31, 2021 and September 30, 2022, the amount outstanding under the term loan under the amended credit agreement, net of debt amortization expense of \$687 and \$358, was \$560,313 and \$535,142, respectively. As of December 31, 2021 and September 30, 2022, the term loan bore interest at a rate equal to LIBOR plus a margin of 1.375% per annum.

Indebtedness under the amended credit facility is unsecured. The amount outstanding on the term loan as of September 30, 2022 requires quarterly payments of \$8,500, and the balance of the loan is due and payable upon the maturity of the term loan on August 8, 2023. The Company is in the process of refinancing its credit facility, and is currently in negotiation with various financial institutions, and the refinancing is expected to close in the fourth quarter of 2022.

The maturity profile of the term loan outstanding as of September 30, 2022, net of debt amortization expense, is as follows:

Year ended	Amount
2022	8,393
2023	526,749
Total	\$ 535,142

Genpact Luxembourg S.à r.l., a wholly-owned subsidiary of the Company, issued \$400,000 aggregate principal amount of 3.375% senior notes in November 2019 (the "2019 Senior Notes"). The 2019 Senior Notes are fully guaranteed by the Company. The total debt issuance cost of \$2,937 incurred in connection with the 2019 Senior Notes offering is being amortized over the life of the 2019 Senior Notes as an additional interest expense. As of December 31, 2021 and September 30, 2022, the amount outstanding under the 2019 Senior Notes, net of debt amortization expense of \$1,702 and \$1,266, was \$398,298 and \$398,734, respectively, which is payable on December 1, 2024.

In March 2021, Genpact Luxembourg S.à r.l. and Genpact USA, Inc., both wholly-owned subsidiaries of the Company, co-issued \$350,000 aggregate principal amount of 1.750% senior notes (the "2021 Senior Notes," and together with the 2019 Senior Notes, the "Senior Notes"). The 2021 Senior Notes are fully guaranteed by the Company. The total debt issuance cost of \$3,032 incurred in connection with the 2021 Senior Notes is being amortized over the life of the 2021 Senior Notes as additional interest expense. As of December 31, 2021 and September 30, 2022, the amount outstanding under the 2021 Senior Notes, net of debt amortization expense of \$2,571 and \$2,121, respectively, was \$347,429 and \$347,879, respectively, which is payable on April 10, 2026.

The Company pays interest on (i) the 2019 Senior Notes semi-annually in arrears on June 1 and December 1 of each year, and (ii) the 2021 Senior Notes semi-annually in arrears on April 10 and October 10 of each year, ending on the maturity dates of December 1, 2024 and April 10, 2026, respectively. The Company, at its option, may redeem the Senior Notes at any time in whole or in part, at a redemption price equal to (i) 100% of the principal amount of the notes redeemed, together with accrued and unpaid interest on the redeemed amount, and (ii) if the notes are redeemed prior to, in the case of the 2019 Senior Notes, November 1, 2024, and in the case of the 2021 Senior Notes, March 10, 2026, a specified "make-whole" premium. The Senior Notes are subject to certain customary covenants, including limitations on the ability of the Company and certain of its subsidiaries to incur debt secured by liens, engage in certain sale and leaseback transactions and consolidate, merge, convey or transfer their assets substantially as an entirety. During the period ended September 30, 2022, the Company and its applicable subsidiaries were in compliance with the covenants. Upon certain change of control transactions, the applicable issuer or issuers will be required to make an offer to repurchase the Senior Notes at a price equal to 101% of the aggregate principal amount of the Senior Notes, plus accrued and unpaid interest. The interest rate payable on the Senior Notes is subject to adjustment if the credit rating of the Senior Notes is downgraded, up to a maximum increase of 2.0%.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

12. Long-term debt (Continued)

A summary of the Company's long-term debt is as follows:

	As of December 31, 2021	As of September 30, 2022
Credit facility, net of amortization expenses	\$ 560,313	\$ 535,142
3.70% 2017 Senior Notes, net of debt amortization expenses	349,869	—
3.375% 2019 Senior Notes, net of debt amortization expenses	398,298	398,734
1.750% 2021 Senior Notes, net of debt amortization expenses	347,429	347,879
Total	\$ 1,655,909	\$ 1,281,755
Current portion	383,433	535,142
Non-current portion	1,272,476	746,613
Total	\$ 1,655,909	\$ 1,281,755

13. Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following:

	As of December 31, 2021	As of September 30, 2022
Accrued expenses	\$ 162,054	\$ 129,877
Accrued employee cost	307,777	230,013
Earn-out consideration	2,501	2,517
Statutory liabilities	67,948	69,857
Retirement benefits	1,746	1,657
Compensated absences	26,596	24,505
Derivative instruments	12,498	49,121
Contract liabilities (Note 20)	160,602	144,441
Finance leases liability	18,549	13,321
Other liabilities	31,169	35,175
	\$ 791,440	\$ 700,484

As September 30, 2022, the Company reclassified certain accrued expenses and other current liabilities amounting to \$7,141 to liabilities held for sale. See Note 8 for additional information.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

14. Other liabilities

Other liabilities consist of the following:

	As of December 31, 2021	As of September 30, 2022
Accrued employee cost	\$ 15,790	\$ 20,647
Earn-out consideration	2,905	—
Retirement benefits	11,993	11,987
Compensated absences	52,023	46,293
Derivative instruments	2,756	10,078
Contract liabilities (Note 20)	80,222	63,868
Finance leases liability	16,297	11,897
Others	63,224	70,643
	<u>\$ 245,210</u>	<u>\$ 235,413</u>

As September 30, 2022, the Company reclassified certain other liabilities amounting to \$859 to liabilities held for sale. See Note 8 for additional information.

15. Employee benefit plans

The Company has employee benefit plans in the form of certain statutory and other programs covering its employees.

Defined benefit plans

In accordance with Indian law, the Company maintains a defined benefit retirement plan covering substantially all of its Indian employees. In accordance with Mexican law, the Company provides termination benefits to all of its Mexican employees. In addition, certain of the Company's subsidiaries in the Philippines, Israel and Japan sponsor defined benefit retirement programs.

Net defined benefit plan costs for the three and nine months ended September 30, 2021 and 2022 include the following components:

	Three months ended September 30,		Nine months ended September 30,	
	2021	2022	2021	2022
Service costs	\$ 3,454	\$ 3,505	\$ 10,528	\$ 10,804
Interest costs	1,363	1,424	4,135	4,394
Amortization of actuarial loss	558	178	1,704	550
Expected return on plan assets	(1,534)	(1,457)	(4,605)	(4,502)
Net defined benefit plan costs	<u>\$ 3,841</u>	<u>\$ 3,650</u>	<u>\$ 11,762</u>	<u>\$ 11,246</u>

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

15. Employee benefit plans (Continued)

Defined contribution plans

During the three and nine months ended September 30, 2021 and 2022, the Company contributed the following amounts to defined contribution plans in various jurisdictions:

	Three months ended September 30,		Nine months ended September 30,	
	2021	2022	2021	2022
India	\$ 9,637	\$ 11,015	\$ 27,445	\$ 32,629
U.S.	5,020	5,060	15,508	16,968
U.K.	4,301	4,676	12,074	16,398
China	6,362	6,772	18,433	20,003
Other regions	3,913	4,351	11,155	13,728
Total	\$ 29,233	\$ 31,874	\$ 84,615	\$ 99,726

Deferred compensation plan

On July 1, 2018, Genpact LLC, a wholly-owned subsidiary of the Company, adopted an executive deferred compensation plan (the "Plan"). The Plan provides a select group of U.S.-based members of Company management with the opportunity to defer from 1% to 80% of their base salary and from 1% to 100% of their qualifying bonus compensation (or such other minimums or maximums as determined by the Plan administrator from time to time) pursuant to the terms of the Plan. Participant deferrals are 100% vested at all times. The Plan also allows for discretionary supplemental employer contributions by the Company, in its sole discretion, which will be subject to a two-year vesting schedule (50% vesting on the one-year anniversary of approval of the contribution and 50% vesting on the second year anniversary of approval of the contribution) or such other vesting schedule as determined by the Company. However, no such contribution has been made by the Company to date.

The Plan also provides an option for participants to elect to receive deferred compensation and earnings thereon on either fixed date(s) no earlier than 2 years following the applicable Plan year (or end of the applicable performance period for performance-based bonus compensation) or following a separation from service, in each case either in a lump sum or in annual installments over a term of up to 15 years. Participants can elect to change or re-defer their rights to receive the deferred compensation until the 10th anniversary following their separation from service, subject to fulfillment of certain conditions. Each Plan participant's compensation deferrals are credited or debited with notional investment gains and losses equal to the performance of selected hypothetical investment funds offered under the Plan and elected by the participant.

The Company has investments in funds held in Company-owned life insurance policies which are held in a Rabbi Trust that are classified as trading securities. Management determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The securities are classified as trading securities because they are held for resale in anticipation of short-term fluctuations in market prices. The trading securities are stated at fair value.

The liability for the deferred compensation plan was \$38,007 and \$36,583 as of December 31, 2021 and September 30, 2022, respectively, and is included in "accrued expenses and other current liabilities" and "other liabilities" in the consolidated balance sheets.

In connection with the administration of the Plan, the Company has purchased Company-owned life insurance policies insuring the lives of certain employees. The cash surrender value of these policies was \$38,584 and \$37,183 as of December 31, 2021 and September 30, 2022, respectively. The cash surrender value of these insurance policies is included in "other assets" in the consolidated balance sheets.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

15. Employee benefit plans (Continued)

During the nine months ended September 30, 2021 and 2022, the change in the fair value of Plan assets was \$2,658 and \$(10,011), respectively, and for the three months ended September 30, 2021 and 2022, the change in the fair value of Plan assets was \$(84) and \$(1,964), respectively, which is included in "other income (expense), net," in the consolidated statements of income. During the nine months ended September 30, 2021 and 2022, the change in the fair value of deferred compensation liabilities was \$2,526 and \$(10,035), respectively, and for the three months ended September 30, 2021 and 2022, the change in the fair value of deferred compensation liabilities was \$(159) and \$(1,977), respectively, which is included in "selling, general and administrative expenses."

16. Stock-based compensation

The Company has issued options under the Genpact Limited 2007 Omnibus Incentive Compensation Plan (the "2007 Omnibus Plan") and the Genpact Limited 2017 Omnibus Incentive Compensation Plan (the "2017 Omnibus Plan") to eligible persons, including employees, directors and certain other persons associated with the Company.

Under the 2007 Omnibus Plan, shares underlying options forfeited, expired, terminated or cancelled under any of the Company's predecessor plans were added to the number of shares otherwise available for grant under the 2007 Omnibus Plan. The 2007 Omnibus Plan was amended and restated on April 11, 2012 to increase the number of common shares authorized for issuance by 5,593,200 shares to 15,000,000 shares. Further, during the year ended December 31, 2012, the number of common shares authorized for issuance under the 2007 Omnibus Plan was increased by 8,858,823 shares as a result of a one-time adjustment to outstanding unvested share awards in connection with a special dividend payment.

On May 9, 2017, the Company's shareholders approved the adoption of the 2017 Omnibus Plan, pursuant to which 15,000,000 Company common shares are available for issuance. The 2017 Omnibus Plan was amended and restated on April 5, 2019 and April 5, 2022 to increase the number of common shares authorized for issuance by 8,000,000 shares to 23,000,000 shares and by 3,500,000 shares to 26,500,000 shares, respectively. No grants may be made under the 2007 Omnibus Plan after the date of adoption of the 2017 Omnibus Plan. Grants that were outstanding under the 2007 Omnibus Plan as of the date of Company's adoption of the 2017 Omnibus Plan remain subject to the terms of the 2007 Omnibus Plan.

Stock-based compensation costs relating to the foregoing plans during the nine months ended September 30, 2021 and September 30, 2022 were \$57,554 and \$53,712, respectively, and for the three months ended September 30, 2021 and September 30, 2022 were \$21,150 and \$18,873, respectively. These costs have been allocated to "cost of revenue" and "selling, general and administrative expenses."

Stock options

All options granted under the 2007 and 2017 Omnibus Plans are exercisable into common shares of the Company, have a contractual period of ten years and vest over three to five years unless specified otherwise in the applicable award agreement. The Company recognizes compensation cost over the vesting period of the option.

Compensation cost is determined at the date of grant by estimating the fair value of an option using the Black-Scholes option-pricing model.

The following table shows the significant assumptions used in determining the fair value of options granted in the nine months ended September 30, 2021 and September 30, 2022. The Company granted options covering 1,831,180 common shares in the nine months ended September 30, 2021.

	Nine months ended September 30, 2021		Nine months ended September 30, 2022	
Dividend yield	0.84 %	— 1.08%		0.96 %
Expected life (in months)		84		84
Risk-free rate of interest	1.12 %	— 1.37%		1.71 %
Volatility	26.05 %	— 26.18%		26.29 %

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

16. Stock-based compensation (Continued)

A summary of stock option activity during the nine months ended September 30, 2022 is set out below:

	Nine Months Ended September 30, 2022			
	Shares arising out of options	Weighted average exercise price	Weighted average remaining contractual life (years)	Aggregate intrinsic value
Outstanding as of January 1, 2022	8,008,296	31.30	6.1	—
Granted	475,695	52.12	—	—
Forfeited	(70,841)	41.46	—	—
Expired	—	—	—	—
Exercised	(110,000)	26.87	—	1,789
Outstanding as of September 30, 2022	8,303,150	32.46	5.5	100,968
Vested as of September 30, 2022 and expected to vest thereafter (Note a)	7,783,195	31.70	5.5	99,577
Vested and exercisable as of September 30, 2022	3,766,735	24.73	3.3	71,706
Weighted average grant date fair value of grants during the period	14.19			

(a) Options expected to vest reflect an estimated forfeiture rate.

As of September 30, 2022, the total remaining unrecognized stock-based compensation cost for options expected to vest amounted to \$21,073, which will be recognized over the weighted average remaining requisite vesting period of 3.0 years.

Restricted share units

The Company has granted restricted share units (“RSUs”) under the 2007 and 2017 Omnibus Plans. Each RSU represents the right to receive one common share. The fair value of each RSU is the market price of one common share of the Company on the date of the grant. The RSUs granted to date have graded vesting schedules of three months to four years. The compensation expense is recognized on a straight-line basis over the vesting term. A summary of RSU activity during the nine months ended September 30, 2022 is set out below:

	Nine Months Ended September 30, 2022	
	Number of Restricted Share Units	Weighted Average Grant Date Fair Value
Outstanding as of January 1, 2022	759,507	42.29
Granted	206,280	45.66
Vested (Note a)	(28,866)	47.63
Forfeited	(54,200)	42.49
Outstanding as of September 30, 2022	882,721	42.89
Expected to vest (Note b)	803,557	

(a) 28,866 RSUs vested during the nine months ended September 30, 2022 in respect of which 19,992 shares (net of minimum statutory tax withholding) were issued during the nine months ended September 30, 2022.

(b) The number of RSUs expected to vest reflects the application of an estimated forfeiture rate.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

16. Stock-based compensation (Continued)

49,513 RSUs vested in the year ended December 31, 2020, in respect of which 49,446 shares were issued during the nine months ended September 30, 2022 after withholding shares to the extent required to satisfy minimum statutory withholding obligations.

7,863 RSUs vested in the year ended December 31, 2021, in respect of which 5,496 shares were issued during the nine months ended September 30, 2022 after withholding shares to the extent required to satisfy minimum statutory withholding obligations.

As of September 30, 2022, the total remaining unrecognized stock-based compensation cost related to RSUs amounted to \$15,478, which will be recognized over the weighted average remaining requisite vesting period of 2.0 years.

Performance units

The Company also grants stock awards in the form of performance units ("PUs") and has granted PUs under both the 2007 and 2017 Omnibus Plans.

Each PU represents the right to receive one common share at a future date based on the Company's performance against specified targets. PUs granted to date have vesting schedules of six months to three years. The fair value of each PU is the market price of one common share of the Company on the date of grant and assumes that performance targets will be achieved. PUs granted under the plans are subject to cliff vesting. The compensation expense for such awards is recognized on a straight-line basis over the vesting terms. During the performance period, the Company's estimate of the number of shares to be issued is adjusted upward or downward based upon the probability of achievement of the performance targets. The ultimate number of shares issued and the related compensation cost recognized is based on a comparison of the final performance metrics to the specified targets.

A summary of PU activity during the nine months ended September 30, 2022 is set out below:

	Nine Months Ended September 30, 2022		
	Number of Performance Units	Weighted Average Grant Date Fair Value	Maximum Shares Eligible to Receive
Outstanding as of January 1, 2022	4,583,155	39.40	4,583,155
Granted	1,590,794	44.50	3,181,588
Vested (Note a)	(2,161,789)	34.61	(2,161,789)
Forfeited	(445,773)	43.46	(577,995)
Adjustment upon final determination of level of performance goal achievement (Note b)	28,325	44.01	28,325
Outstanding as of September 30, 2022	3,594,712	44.07	5,053,284
Expected to vest (Note c)	3,063,863		

- (a) 2,161,789 PUs that vested during the period were net settled upon vesting by issuing 1,300,511 shares (net of minimum statutory tax withholding).
- (b) Represents an adjustment made in March 2022 to the number of shares subject to the PUs granted in 2021 upon certification of the level of achievement of the performance targets underlying such awards.
- (c) The number of PUs expected to vest reflects the application of an estimated forfeiture rate.

As of September 30, 2022, the total remaining unrecognized stock-based compensation cost related to PUs amounted to \$72,523, which will be recognized over the weighted average remaining requisite vesting period of 1.8 years.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

16. Stock-based compensation (Continued)

Employee Stock Purchase Plan (ESPP)

On May 1, 2008, the Company adopted the Genpact Limited U.S. Employee Stock Purchase Plan and the Genpact Limited International Employee Stock Purchase Plan (together, the "ESPP"). In April 2018, these plans were amended and restated, and their terms were extended to August 31, 2028.

The ESPP allows eligible employees to purchase the Company's common shares through payroll deductions at 90% of the closing price of the Company's common shares on the last business day of each purchase interval. The dollar amount of common shares purchased under the ESPP may not exceed 15% of the participating employee's base salary, subject to a cap of \$25 per employee per calendar year. With effect from September 1, 2009, the offering periods commence on the first business day in March, June, September and December of each year and end on the last business day of the subsequent May, August, November and February. 4,200,000 common shares have been reserved for issuance in the aggregate over the term of the ESPP.

During the nine months ended September 30, 2021 and 2022, 216,378 and 253,377 common shares, respectively, were issued under the ESPP.

The ESPP is considered compensatory under the FASB guidance on Compensation-Stock Compensation.

The compensation expense for the ESPP is recognized in accordance with the FASB guidance on Compensation-Stock Compensation. The compensation expense for the ESPP during the nine months ended September 30, 2021 and 2022 was \$1,050 and \$1,182, respectively, and for the three months ended September 30, 2021 and 2022 was \$335 and \$329, respectively, and has been allocated to cost of revenue and selling, general and administrative expense.

17. Capital stock

Share repurchases

The Board of Directors of the Company (the "Board") has authorized repurchases of up to \$1,750,000 under the Company's existing share repurchase program. Under the program, shares may be purchased in privately negotiated and/or open market transactions, including under plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

During the nine months ended September 30, 2021 and 2022, the Company repurchased 3,592,409 and 4,067,044 of its common shares, respectively, on the open market at a weighted average price of \$40.96 and \$44.75 per share, respectively, for an aggregate cash amount of \$147,152 and \$182,012, respectively. All repurchased shares have been retired.

The Company records repurchases of its common shares on the settlement date of each transaction. Shares purchased and retired are deducted to the extent of their par value from common stock and from retained earnings for the excess over par value. Direct costs incurred to acquire the shares are included in the total cost of the shares purchased. For the nine months ended September 30, 2021 and 2022, retained earnings were reduced by the direct costs related to share repurchases of \$72 and \$81, respectively.

\$156,899 remained available for share repurchases under the Company's existing share repurchase program as of September 30, 2022. This repurchase program does not obligate the Company to acquire any specific number of shares and does not specify an expiration date.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

17. Capital stock (Continued)

Dividend

On February 9, 2021, the Company announced that its Board had approved a 10% increase in its quarterly cash dividend to \$0.1075 per share, up from \$0.0975 per share in 2020, representing an annual dividend of \$0.43 per common share, up from \$0.39 per share in 2020, payable to holders of the Company's common shares. On March 19, 2021, June 23, 2021 and September 24, 2021, the Company paid a dividend of \$0.1075 per share, amounting to \$20,115, \$20,133 and \$20,213 in the aggregate, to shareholders of record as of March 10, 2021, June 11, 2021 and September 10, 2021, respectively.

On February 10, 2022, the Company announced that its Board had approved a 16% increase in its quarterly cash dividend to \$0.125 per share, up from \$0.1075 per share in 2021, representing a planned annual dividend of \$0.50 per common share, up from \$0.43 per share in 2021, payable to holders of the Company's common shares. On March 23, 2022, June 24, 2022 and September 23, 2022, the Company paid a dividend of \$0.125 per share, amounting to \$23,134, \$22,935 and \$22,873 in the aggregate, to shareholders of record as of March 10, 2022, June 10, 2022 and September 9, 2022, respectively.

18. Earnings per share

The Company calculates earnings per share in accordance with FASB guidance on earnings per share. Basic and diluted earnings per common share give effect to the change in the number of Company common shares outstanding. The calculation of basic earnings per common share is determined by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the respective periods. The potentially dilutive shares, consisting of outstanding options on common shares, restricted share units, common shares to be issued under the ESPP and performance units, have been included in the computation of diluted net earnings per share and the number of weighted average shares outstanding, except where the result would be anti-dilutive.

The number of shares subject to stock awards outstanding but not included in the computation of diluted earnings per common share because their effect was anti-dilutive is 1,698,735 and 2,757,114 for the nine months ended September 30, 2021 and 2022, respectively, and 1,556,671 and 2,667,958 for the three months ended September 30, 2021 and 2022, respectively.

	Three months ended September 30,		Nine months ended September 30,	
	2021	2022	2021	2022
Net income	\$ 102,386	\$ 95,843	\$ 296,363	\$ 263,692
Weighted average number of common shares used in computing basic earnings per common share	187,856,026	183,312,013	187,945,234	184,456,047
Dilutive effect of stock-based awards	5,303,903	4,087,191	4,940,018	3,818,373
Weighted average number of common shares used in computing dilutive earnings per common share	193,159,929	187,399,204	192,885,252	188,274,420
Earnings per common share				
Basic	\$ 0.55	\$ 0.52	\$ 1.58	\$ 1.43
Diluted	\$ 0.53	\$ 0.51	\$ 1.54	\$ 1.40

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

19. Segment reporting

The Company manages various types of business process and transformation services in an integrated manner for clients in various industries and geographic locations. The Company's operating segments are significant strategic business units that align its products and services with how it manages its business, approaches key markets and interacts with its clients.

During the second quarter of 2022, the Company renamed its three reportable segments. Beginning in the second quarter of 2022, the Company's: (1) Banking, Capital Markets and Insurance segment has been renamed the Financial Services segment; (2) Consumer Goods, Retail, Life Sciences and Healthcare segment has been renamed the Consumer and Healthcare segment; and (3) High Tech, Manufacturing and Services segment has been renamed the High Tech and Manufacturing segment.

The Company's Chief Executive Officer, who has been identified as the Chief Operating Decision Maker ("CODM"), reviews operating segment revenue, which is a GAAP measure, and operating segment adjusted income from operations ("AOI"), which is a non-GAAP measure. The Company does not allocate, and therefore the CODM does not evaluate, stock-based compensation expenses, amortization and impairment of acquired intangible assets, foreign exchange gain/(losses), interest income/(expense), restructuring expenses, acquisition related expenses, any losses or gains from businesses held for sale, including impairment charges, other income/(expense), or income taxes by segment. The Company's operating assets and liabilities pertain to multiple segments. The Company manages assets and liabilities on a total company basis, not by operating segment, and therefore asset and liabilities information and capital expenditures by operating segment are not presented to the CODM and are not reviewed by the CODM.

The CODM continues to review the operating segment revenue, which is a GAAP measure, and operating segment adjusted income from operations, which is a non-GAAP measure.

Revenues and adjusted income from operations for each of the Company's segments for the three months ended September 30, 2021 were as follows:

	Net revenues			AOI
	Data-Tech-AI	Digital operations	Total	
Financial Services	107,683	150,838	258,521	32,514
Consumer and Healthcare	168,801	219,268	388,069	63,681
High Tech and Manufacturing	151,770	214,971	366,741	68,263
Total reportable segment	428,254	585,077	1,013,331	164,458
Others#	554	1,852	2,406	4,484
Total	428,808	586,929	1,015,737	168,942
Stock-based compensation				(21,485)
Amortization and impairment of acquired intangible assets (other than included above)				(13,688)
Foreign exchange gains (losses), net				2,733
Interest income (expense), net				(12,765)
Income tax expense				(21,351)
Net income				102,386

#Revenues, net for "Others" primarily represents the impact of foreign exchange fluctuations, which is not allocated to the Company's segments for management's internal reporting purposes. Adjusted income from operations for "Others" primarily represents the impact of over-absorption of overhead and foreign exchange fluctuations, which are not allocated to the Company's segments for management's internal reporting purposes.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

19. Segment reporting (Continued)

Revenues and adjusted income from operations for each of the Company's segments for the three months ended September 30, 2022 were as follows:

	Net revenues			AOI
	Data-Tech-AI	Digital operations	Total	
Financial Services	137,629	166,216	303,845	41,008
Consumer and Healthcare	194,154	218,695	412,849	49,598
High Tech and Manufacturing	188,455	236,837	425,292	69,553
Total reportable segment	520,238	621,748	1,141,986	160,159
Others*	(10,508)	(20,441)	(30,949)	21,591
Total	509,730	601,307	1,111,037	181,750
Business held for sale (refer to Note (a) below and Note 8)			(3,932)	7,069
Total (excluding business held for sale - refer to Note (a) below and Note 8)			1,107,105	188,819
Stock-based compensation				(19,202)
Amortization and impairment of acquired intangible assets (other than included above)				(10,516)
Foreign exchange gains (losses), net				3,867
Interest income (expense), net				(13,399)
Business held for sale (refer to Note (a) below and Note 8)				(7,069)
Impairment charge on assets classified as held for sale (refer to Note (a) below and Note 8)				(21,426)
Income tax expense				(25,231)
Net income				95,843

(a) During the second quarter of 2022, the Company's management approved a plan to divest a business that comprises part of the Company's Consumer and Healthcare segment. The revenues and associated losses, including an impairment charge recorded in the third quarter of 2022, attributable to this business have been excluded from the computation of adjusted operating income margin with effect from April 1, 2022, as management believes that excluding these items provides useful information about the Company's financial performance and underlying business trends.

*Revenues, net for "Others" primarily represents the impact of foreign exchange fluctuations, which is not allocated to the Company's segments for management's internal reporting purposes. Adjusted income from operations for "Others" primarily represents the impact of under-absorption of overhead, unallocated allowance for credit losses and foreign exchange fluctuations, which are not allocated to the Company's segments for management's internal reporting purposes.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

19. Segment reporting (Continued)

Revenues and adjusted income from operations for each of the Company's segments for the nine months ended September 30, 2021 were as follows:

	Net revenues			AOI
	Data-Tech-AI	Digital operations	Total	
Financial Services	293,207	457,383	750,590	98,972
Consumer and Healthcare	476,822	624,361	1,101,183	184,647
High Tech and Manufacturing	434,143	647,623	1,081,766	203,915
Total reportable segment	1,204,172	1,729,367	2,933,539	487,534
Others##	4,340	12,055	16,395	21,087
Total	1,208,512	1,741,422	2,949,934	508,621
Stock-based compensation				(58,604)
Amortization and impairment of acquired intangible assets (other than included above)				(43,977)
Foreign exchange gains (losses), net				11,529
Interest income (expense), net				(38,198)
Income tax expense				(83,008)
Net income				296,363

##Revenues, net for "Others" primarily represents the impact of foreign exchange fluctuations, which is not allocated to the Company's segments for management's internal reporting purposes. Adjusted income from operations for "Others" primarily represents the impact of over-absorption of overhead and foreign exchange fluctuations, which are not allocated to the Company's segments for management's internal reporting purposes.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

19. Segment reporting (Continued)

Revenues and adjusted income from operations for each of the Company's segments for the nine months ended September 30, 2022 were as follows:

	Net revenues			AOI
	Data-Tech-AI	Digital operations	Total	
Financial Services	391,485	481,116	872,601	102,747
Consumer and Healthcare	560,561	662,721	1,223,282	158,290
High Tech and Manufacturing	530,975	694,725	1,225,700	207,850
Total reportable segment	1,483,021	1,838,562	3,321,583	468,887
Others**	(18,002)	(34,954)	(52,956)	48,455
Total	1,465,019	1,803,608	3,268,627	517,342
Business held for sale (refer to Note (b) below and Note 8)			(8,843)	14,291
Total (excluding business held for sale - refer to Note (b) below and Note 8)			3,259,784	531,633
Stock-based compensation				(54,894)
Amortization and impairment of acquired intangible assets (other than included above)				(32,709)
Foreign exchange gains (losses), net				9,312
Interest income (expense), net				(36,691)
Business held for sale (refer to Note (b) below and Note 8)				(14,291)
Impairment charge on assets classified as held for sale (refer to Note (b) below and Note 8)				(21,426)
Restructuring expenses (refer to Note (c) below and Note 25)				(38,815)
Income tax expense				(78,427)
Net income				263,692

(b) During the second quarter of 2022, the Company's management approved a plan to divest a business that comprises part of the Company's Consumer and Healthcare segment. The revenues and associated losses, including an impairment charge recorded in the third quarter of 2022, attributable to this business have been excluded from the computation of adjusted operating income margin with effect from April 1, 2022, as management believes that excluding these items provides useful information about the Company's financial performance and underlying business trends.

(c) The Company does not allocate these charges to individual segments in internal management reports used by the CODM. Accordingly, such expenses are included in the Company's segment reporting as "unallocated costs."

**Revenues, net for "Others" primarily represents the impact of foreign exchange fluctuations, which is not allocated to the Company's segments for management's internal reporting purposes. Adjusted income from operations for "Others" primarily represents the impact of under-absorption of overhead, unallocated allowance for credit losses and foreign exchange fluctuations, which are not allocated to the Company's segments for management's internal reporting purposes.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

20. Net revenues

Disaggregation of revenue

In the following table, the Company's revenue is disaggregated by the nature of services provided:

	Three months ended September 30,		Nine months ended September 30,	
	2021	2022	2021	2022
Data-Tech-AI	\$ 428,808	\$ 509,730	\$ 1,208,512	\$ 1,465,019
Digital Operations	586,929	601,307	1,741,422	1,803,608
Total net revenues	\$ 1,015,737	\$ 1,111,037	\$ 2,949,934	\$ 3,268,627

All three of the Company's segments include revenue from both Data-Tech-AI and Digital Operations. See Note 19 for additional information.

During the second quarter of 2022, the Company's management modified the manner in which it disaggregates revenue for reporting and internal tracking purposes, and the Company now reports revenue disaggregated by the nature of services provided to the client, namely either Data-Tech-AI or Digital Operations. Prior to the second quarter of 2022, the Company disaggregated its revenue as revenue from the General Electric Company (GE) or revenue from Global Clients (other than GE).

The Company has evaluated the impact of the COVID-19 pandemic on the Company's net revenues for the three and nine months ended September 30, 2021 and 2022, respectively, to ensure that revenue is recognized after considering all impacts to the extent currently known. Impacts observed include constraints on the Company's ability to render services, whether due to full or partial shutdowns of the Company's facilities or travel restrictions, penalties relating to breaches of service level agreements, and contract terminations or contract performance delays initiated by clients. The Company's net revenues for the three and nine months ended September 30, 2021 were lower than expected before the onset of the pandemic, primarily due to delays in obtaining client approvals to shift to a virtual, work-from-home operating environment, whether as a result of regulatory constraints or due to privacy or security concerns. The COVID-19 pandemic did not have a significant impact on the Company's net revenues for the three and nine months ended September 30, 2022.

Due to the nature of the pandemic, the Company will continue to monitor developments to identify significant uncertainties relating to revenue in future periods.

Contract balances

Accounts receivable include amounts for services that the Company has performed but for which payment has not been received. The Company typically follows a 30-day billing cycle and, as such, at any point in time may have accrued up to 30 days of revenues that have not been billed. The Company has determined that in instances where the timing of revenue recognition differs from the timing of invoicing, the related contracts generally do not include a significant financing component. Refer to Note 4 for details on the Company's accounts receivable and allowance for credit losses.

The following table shows the details of the Company's contract balances:

	As of December 31, 2021	As of September 30, 2022
Contract assets (Note a)	\$ 13,741	\$ 18,646
Contract liabilities (Note b)		
Deferred transition revenue	\$ 155,077	\$ 136,845
Advance from customers	\$ 85,747	\$ 71,464

(a) Included in "prepaid expenses and other current assets" and "other assets" in the consolidated balance sheet.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

20. Net revenues (Continued)

(b) Included in "accrued expenses and other current liabilities" and "other liabilities" in the consolidated balance sheet.

As of September 30, 2022, the Company reclassified certain contract assets and contract liabilities of \$2,270 and \$2,038, respectively, to assets and liabilities held for sale. See Note 8 for additional information.

Contract assets represent the contract acquisition fees or other upfront fees paid to a customer. Such costs are amortized over the expected period of benefit and recorded as an adjustment to the transaction price and deducted from revenue. The Company's assessment did not indicate any significant impairment losses on its contract assets for the periods presented.

Contract liabilities include that portion of revenue for which payments have been received in advance from customers. The Company also defers revenues attributable to certain process transition activities for which costs have been capitalized by the Company as contract fulfillment costs. Consideration received from customers, if any, relating to such transition activities is also included as part of contract liabilities. The contract liabilities are included within "Accrued expenses and other current liabilities" and "Other liabilities" in the unaudited consolidated balance sheets. The revenues are recognized as (or when) the performance obligation is fulfilled under the contract with the customer.

Changes in the Company's contract asset and liability balances during the three and nine months ended September 30, 2021 and 2022 were a result of normal business activity and not materially impacted by any other factors.

Revenue recognized during the three months ended September 30, 2021 and 2022 that was included in the Company's contract liabilities balance at the beginning of the period was \$60,756 and \$63,762, respectively.

Revenue recognized during the nine months ended September 30, 2021 and 2022 that was included in the Company's contract liabilities balance at the beginning of the period was \$128,628 and \$129,046, respectively.

The following table includes estimated revenue expected to be recognized in the future related to remaining performance obligations as of September 30, 2022:

Particulars	Total	Less than 1 year	1-3 years	3-5 years	After 5 years
Transaction price allocated to remaining performance obligations	\$ 208,309	\$ 144,441	\$ 52,277	\$ 10,494	\$ 1,097
Transaction price allocated to remaining performance obligations relating to business held for sale	\$ 2,038	\$ 2,038	\$ —	\$ —	\$ —

The following table provides details of the Company's contract cost assets:

Particulars	Three months ended September 30,				Nine months ended September 30,			
	2021		2022		2021		2022	
	Sales incentive programs	Transition activities	Sales incentive programs	Transition activities	Sales incentive programs	Transition activities	Sales incentive programs	Transition activities
Opening balance	\$ 31,559	\$ 210,747	\$ 29,186	\$ 198,401	\$ 33,390	\$ 192,507	\$ 32,296	\$ 206,498
Closing balance	31,058	209,320	28,718	189,419	31,058	209,320	28,718	189,419
Amortization	5,041	23,028	6,632	23,767	14,576	58,644	19,220	66,180

As of September 30, 2022, the Company reclassified certain contract assets amounting to \$1,417 to assets and liabilities held for sale. See Note 8 for additional information.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

21. Other operating (income) expense, net

	Three months ended September 30,		Nine months ended September 30,	
	2021	2022	2021	2022
Write-down of intangible assets and property, plant and equipment	\$ —	\$ —	\$ 915	\$ 1,377
Write-down of operating right-of-use assets and other assets*	—	—	—	20,307
Impairment charge on intangible assets and goodwill held-for-sale	—	21,426	—	21,426
Other operating income	(93)	(489)	(1,132)	(953)
Other operating (income) expense, net	\$ (93)	\$ 20,937	\$ (217)	\$ 42,157

*See Notes 10 and 25 for additional information about other operating (income) expense, net for the three and nine months ended September 30, 2022.

22. Interest income (expense), net

	Three months ended September 30,		Nine months ended September 30,	
	2021	2022	2021	2022
Interest income	\$ 2,068	\$ 1,440	\$ 4,544	\$ 4,042
Interest expense	(14,833)	(14,839)	(42,742)	(40,733)
Interest income (expense), net	\$ (12,765)	\$ (13,399)	\$ (38,198)	\$ (36,691)

23. Income taxes

The Company determines its tax provision for interim periods using an estimate of its annual effective tax rate adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the Company updates its estimate of the annual effective tax rate, and if its estimated tax rate changes, the Company makes a cumulative adjustment.

The Company's effective tax rate ("ETR") was 20.8% for the three months ended September 30, 2022, up from 17.3% for the three months ended September 30, 2021. The increase in the Company's ETR in the three months ended September 30, 2022 is primarily due to a lower mix of benefits recorded in the three months ended September 30, 2022 compared to the three months ended September 30, 2021.

The following table summarizes activities related to the Company's unrecognized tax benefits for uncertain tax positions for the nine months ended September 30, 2022:

	Nine months ended September 30, 2022
Opening balance at January 1	\$ 25,651
Increase related to prior year tax positions, including recorded in acquisition accounting	16
Decrease related to prior year tax positions	(1,678)
Decrease related to prior year tax positions due to lapse of applicable statute of limitation	(84)
Effect of exchange rate changes	(1,232)
Closing balance at September 30	\$ 22,673

As of December 31, 2021 and September 30, 2022, the Company had unrecognized tax benefits amounting to 25,651 and \$22,673, respectively, which, if recognized, would impact the Company's effective tax rate.

As of December 31, 2021 and September 30, 2022, the Company had accrued \$2,842 and \$2,904, respectively, in interest and \$628 and \$528, respectively, for penalties relating to unrecognized tax benefits.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

23. Income taxes (Continued)

During the year ended December 31, 2021 and the nine months ended September 30, 2022, the Company recognized approximately \$(13,851) and \$(664), respectively, in interest related to income taxes.

24. Commitments and contingencies

Capital commitments

As of December 31, 2021 and September 30, 2022, the Company has committed to spend \$13,317 and \$22,403, respectively, under agreements to purchase property, plant and equipment. This amount is net of capital advances paid in respect of these purchases.

Bank guarantees

The Company has outstanding bank guarantees and letters of credit amounting to \$7,865 and \$7,683 as of December 31, 2021 and September 30, 2022, respectively. Bank guarantees are generally provided to government agencies and excise and customs authorities for the purpose of maintaining a bonded warehouse. These guarantees may be revoked if the government agencies suffer any losses or damages through the breach of any of the covenants contained in the agreements governing such guarantees.

Other commitments

Certain units of the Company's Indian subsidiaries are established as Software Technology Parks of India units or Special Economic Zone ("SEZ") units under the relevant regulations issued by the Government of India. These units are exempt from customs and other duties on imported and indigenous capital goods, stores and spares. SEZ units are also exempt from the Goods and Services Tax ("GST") that was introduced in India in 2017. The Company has undertaken to pay taxes and duties, if any, in respect of capital goods, stores, spares and services consumed duty-free, in the event that certain terms and conditions are not fulfilled.

Contingency

(a) In February 2019, there was a judicial pronouncement in India with respect to defined contribution benefit payments interpreting certain statutory defined contribution obligations of employees and employers. It is not currently clear whether the interpretation set out in the pronouncement has retrospective application. If applied retrospectively, the interpretation would result in an increase in contributions payable by the Company for past periods for certain of its India-based employees. There are numerous interpretative challenges concerning the retrospective application of the judgment. Due to such challenges and a lack of interpretive guidance, and based on legal advice the Company has obtained on the matter, it is currently impracticable to reliably estimate the timing and amount of any payments the Company may be required to make. Accordingly, the Company plans to obtain further clarity and will evaluate the amount of a potential provision, if any.

(b) The Indian taxing authorities ("ITA") have initiated proceedings to examine the availability of a tax exemption claimed by the Company in respect of exports of services and related refunds under the Indian Goods and Services ("GST") tax regime and the previous service tax regime. In the second quarter of 2020, the ITA began to challenge or reject the Company's Indian GST and service tax refunds in certain Indian states. In total, refunds of \$28,535 have been denied or challenged by the ITA. Additional refunds may be denied. The Company is pursuing appeals of the denied refunds before relevant appellate authorities. The Company had requested these refunds pursuant to the tax exemption available for exports under the previous service tax regime as well as the current GST regime in respect of services performed by the Company in India for affiliates and clients outside of India. In denying the refunds, the ITA have taken the position that the services provided are local services, which interpretation, if correct, would make the service tax and GST exemption on exports unavailable to the Company in respect of such services. Additional potentially material challenges and assessments may result from ongoing proceedings related to service tax recovery. The Company believes that the denial of the refunds claimed pursuant to the service tax and GST exemption is incorrect and that the risk that the liability will materialize is remote. The Government of India has issued an administrative circular which supports the Company's position, and the Company believes that the appellate authorities will reverse the previous orders denying refunds owed to the Company. Accordingly, no reserve has been provided as of September 30, 2022.

GENPACT LIMITED AND ITS SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(In thousands, except per share data and share count)

24. Commitments and contingencies (Continued)

(c) The ITA have also issued assessment orders to certain subsidiaries of the Company seeking to assess income tax on certain transactions that occurred in 2013 and 2015. The Company has received demands for potential tax claims related to these orders in an aggregate amount of \$209,042, including interest through the date of the orders. This amount excludes penalties or interest accrued since the date of the orders. The Company is pursuing appeals before the relevant appellate authorities in respect of these orders. The Income Tax Appellate Tribunal of India (the "Tribunal") has accepted the legal arguments made by the Company and ruled in favor of the Company in relation to demands of \$100,589, and the corresponding assessment order has been cancelled. The ITA may appeal the Tribunal's ruling before a higher court. Based on its evaluation of the facts underlying the transactions and legal advice received on the matter, the Company believes that it is more likely than not that the Company's position will ultimately prevail in respect of these transactions. Accordingly, no reserve has been provided as of September 30, 2022.

(d) In September 2020, the Indian Parliament approved the Code on Social Security, 2020 (the "Code"), which will impact the Company's contributions to its defined contribution and defined benefit plans for employees based in India. The date the changes will take effect is not yet known and the rules for quantifying the financial impact have not yet been published. The Company will evaluate the impact of the Code on the Company in its financial statements for the period in which the Code becomes effective and the related rules are published.

25. Restructuring

The Company has implemented a flexible, hybrid global delivery model in line with the Company's long-term strategy that incorporates a mix of offshore, onshore, near shore, and remote working. As a result, the Company determined that certain leases and employee roles were no longer needed.

Accordingly, in the second quarter of 2022, the Company recorded a \$38,815 restructuring charge relating to the abandonment of leased office premises and an employee severance charge. Of the total charge of \$38,815, \$21,684 was a non-cash charge (including \$1,377 related to writing down of certain property, plant and equipment) recorded as other operating expense, which pertains to the abandonment of various leased office premises. The Company also recorded a severance charge of \$17,131 in personnel expenses. The Company has sought out one or more third parties to sublease certain office premises from the Company, wherever applicable, instead of abandoning them. However, the Company has not been successful in such attempts, and the Company believes it is unlikely that it will be able to sublease such premises in the foreseeable future. No restructuring costs were incurred related to this restructuring plan in the third quarter of 2022.

26. Subsequent events

Dividend

On October 13, 2022, the Company announced that its Board of Directors has declared a dividend for the fourth quarter of 2022 of \$0.125 per common share, which is payable on December 23, 2022 to shareholders of record as of the close of business on December 9, 2022. The declaration of any future dividends will be at the discretion of the Board of Directors and subject to Bermuda and other applicable laws.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis is meant to provide material information relevant to an assessment of the financial condition and results of operations of our Company, including an evaluation of the amounts and uncertainties of cash flows from operations and from outside sources, so as to allow investors to better view our Company from management's perspective. The following discussion should be read in conjunction with our consolidated financial statements and the related notes that appear elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2021 and with the information under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2021. In addition to historical information, this discussion includes forward-looking statements and information that involves risks, uncertainties and assumptions, including but not limited to those listed below and under "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021.

Special Note Regarding Forward-Looking Statements

We have made statements in this Quarterly Report on Form 10-Q (the "Quarterly Report") in, among other sections, Part I, Item 2—"Management's Discussion and Analysis of Financial Condition and Results of Operations" that are forward-looking statements. In some cases, you can identify these statements by forward-looking terms such as "expect," "anticipate," "intend," "plan," "believe," "seek," "estimate," "could," "may," "shall," "will," "would" and variations of such words and similar expressions, or the negative of such words or similar expressions. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, which in some cases may be based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. In particular, you should consider the numerous risks outlined in Part I, Item 1A—"Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021. For a discussion of risks of which we are aware in relation to the COVID-19 pandemic, see "Our business and results of operations have been adversely impacted and may in the future be adversely impacted by the COVID-19 pandemic" under Part I, Item 1A—"Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021. Many of the risks, uncertainties and other factors identified below have been, and may continue to be, amplified by the COVID-19 pandemic.

Forward-looking statements we may make include, but are not limited to, statements relating to:

- our ability to retain existing clients and contracts;
- our ability to win new clients and engagements;
- our rate of employee attrition;
- the expected value of the statements of work under our master service agreements;
- our beliefs about future trends in our market;
- political, economic or business conditions in countries where we have operations or where our clients operate, including the withdrawal of the United Kingdom, or the U.K., from the European Union, or the EU, commonly known as Brexit, and uncertainty about the future relationship between the U.K. and the EU, and heightened economic and political uncertainty within and among other EU member states;
- expected spending on business process outsourcing, information technology and digital transformation services by clients;
- foreign currency exchange rates;
- the impact of inflation on our and our clients' business operations;
- our ability to convert bookings to revenue;
- our effective tax rate; and

- competition in our industry.

Factors that may cause actual results to differ from expected results include, among others:

- the invasion of Ukraine by Russia and the related sanctions and other measures being implemented or imposed in response thereto, or any potential expansion or escalation of the conflict or its economic disruption beyond its current scope;
- general inflationary pressures and our ability to share increased costs with our clients;
- wage increases in countries where we have operations;
- our ability to hire and retain enough qualified employees to support our operations;
- our ability to effectively price our services and maintain pricing and employee utilization rates;
- the impact of the COVID-19 pandemic on our business, results of operations and financial condition;
- our ability to develop and successfully execute our business strategies;
- our ability to comply with data protection laws and regulations and to maintain the security and confidentiality of personal and other sensitive data of our clients, employees or others;
- telecommunications or technology disruptions or breaches, natural or other disasters, or medical epidemics or pandemics, including the COVID-19 pandemic;
- our dependence on favorable policies and tax laws that may be changed or amended in a manner adverse to us or be unavailable to us in the future, including as a result of tax policy changes in India, and our ability to effectively execute our tax planning strategies;
- our dependence on revenues derived from clients in the United States and Europe and clients that operate in certain industries, such as the financial services industry;
- our ability to successfully consummate or integrate strategic acquisitions or execute divestitures;
- our ability to attract and retain clients and to develop and maintain client relationships on attractive terms;
- our ability to service our defined contribution and benefit plan payment obligations;
- the possible retrospective application of a judicial pronouncement in India regarding our defined contribution and benefit plan payment obligations;
- our relationship with the General Electric Company, or GE, and our ability to maintain relationships with former GE businesses;
- financing terms, including, but not limited to, changes in the London Interbank Offered Rate, or LIBOR, including the pending global phase-out of LIBOR, the development of alternative rates, including the Secured Overnight Financing Rate, and changes to our credit ratings;
- our ability to meet our corporate funding needs, pay dividends, renegotiate our term loan and service debt, including our ability to comply with the restrictions that apply to our indebtedness that may limit our business activities and investment opportunities;
- our ability to grow our business and effectively manage growth and international operations while maintaining effective internal controls;
- restrictions on visas for our employees traveling to North America and Europe;
- fluctuations in currency exchange rates between the currencies in which we transact business;

- our ability to retain senior management;
- the selling cycle for our client relationships;
- legislation in the United States or elsewhere that adversely affects demand for business process outsourcing, information technology and digital transformation services offshore;
- increasing competition in our industry;
- our ability to protect our intellectual property and the intellectual property of others;
- deterioration in the global economic environment and its impact on our clients, including the bankruptcy of our clients;
- regulatory, legislative and judicial developments, including the withdrawal of governmental fiscal incentives;
- the international nature of our business;
- technological innovation;
- our ability to derive revenues from new service offerings and acquisitions; and
- unionization of any of our employees.

Although we believe the expectations reflected in the forward-looking statements are reasonable at the time they are made, we cannot guarantee future results, level of activity, performance or achievements. Achievement of future results is subject to risks, uncertainties, and potentially inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements. We undertake no obligation to update any of these forward-looking statements after the date of this filing to conform our prior statements to actual results or revised expectations. You are advised, however, to consult any further disclosures we make on related subjects in our Form 10-K, Form 10-Q and Form 8-K reports to the Securities and Exchange Commission (the “SEC”).

Continued impact of COVID-19 on our business and results of operations

The COVID-19 pandemic continues to impact the global economy and the markets in which we operate. In the nine months ended September 30, 2022, the pandemic had an insignificant impact on our results. Our Global Leadership Council continues to coordinate and oversee our actions in response to the COVID-19 pandemic.

We will continue to assess the impact of the COVID-19 pandemic on the Company and respond accordingly. The ultimate impact of COVID-19 on our business and the industry in which we operate remains unknown and unpredictable. Our past results may not be indicative of our future performance, and our financial results in future periods, including but not limited to net revenues, income from operations, income from operations margin, net income and earnings per share, may differ materially from historical trends. The extent of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including but not limited to the duration and severity of the pandemic; future variants or subvariants of the COVID-19 virus and the severity of such variants or subvariants; rates of vaccination and the availability and effectiveness of vaccines, including booster shots, and treatments for COVID-19 globally; the macroeconomic impact of the spread of the virus, including the possibility of prolonged decreases in spending on the types of services we provide, deterioration of our clients’ credit, or reduced economic activity; and related government stimulus measures. We are currently unable to predict the full impact that the COVID-19 pandemic will have on our results from operations, financial condition, liquidity and cash flows due to numerous uncertainties, including with respect to the factors listed above. In addition, some of our expenses are less variable in nature and do not closely correlate with revenues, which may lead to a decrease in our profitability.

Impact of Russia’s Military Action in Ukraine on our Business

In February 2022, Russian forces launched significant military action against Ukraine, which has resulted in conflict and disruptions in the region. In response to this action taken by Russia, the United States, the United Kingdom and the

European Union governments, among others, have imposed various sanctions and export-control measures, including comprehensive financial sanctions, targeted at Russia or designated individuals and entities with business interests and/or government connections to Russia or those involved in Russian military activities. Governments have also enhanced export controls and trade sanctions targeting Russia's import of goods. In the event these geopolitical tensions fail to improve or deteriorate, additional governmental sanctions and measures may be enacted.

It is not possible to predict the broader consequences of the conflict, including related geopolitical tensions. The invasion and retaliatory actions taken by the United States and other countries in respect thereof, as well as any counter measures or retaliatory actions by Russia in response, have in certain cases caused and are likely to continue to cause supply chain disruption and inflation, regional instability, geopolitical shifts and could materially adversely affect global trade, currency exchange rates, regional economies and the global economy. While we do not have any operations in Russia or Ukraine, it is difficult to anticipate the impact of any of the foregoing on our business or our clients' businesses, and the conflict and actions taken in response to the conflict could increase our costs, disrupt our supply chain, impair our ability to raise additional capital when needed on acceptable terms, if at all, or otherwise adversely affect our business, financial condition and results of operations. To date, we do not believe Russia's military action in Ukraine and governmental actions in response thereto have had a material impact on our business, financial position or operations. We continue to monitor the situation closely.

For additional information about the risks we face in relation to the COVID-19 pandemic and Russia's invasion of Ukraine, see Part I, Item 1A—"Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021.

Overview

We are a global professional services firm that makes business transformation real. We drive digital-led innovation and run digitally-enabled intelligent operations for our clients, guided by our experience running thousands of processes for hundreds of Fortune Global 500 clients. We have over 117,700 employees serving clients in key industry verticals from more than 30 countries. Our registered office is located at Canon's Court, 22 Victoria Street, Hamilton HM 12, Bermuda.

In the quarter ended September 30, 2022, we recorded net revenues of \$1,111.0 million, of which \$509.7 million, or 45.9%, was from Data-Tech-AI services, with the remaining 601.3 million, or 54.1%, from Digital Operations services.

Certain Acquisitions

On December 31, 2021, we acquired 100% of the outstanding equity/limited liability company interests in Hoodoo Digital, LLC, a Utah limited liability company, for total purchase consideration of \$66.7 million. This amount represents cash consideration of \$64.4 million, net of cash acquired of \$2.3 million. This acquisition furthers our strategy to fuse experience and process innovation to help clients drive end-to-end digital transformation. Hoodoo's expertise with Adobe Experience Manager and other Adobe applications complements our existing end-to-end client solution that seamlessly integrates digital content, e-commerce, data analytics, and marketing operations. Goodwill arising from the acquisition amounting to \$46.0 million has been allocated among our three reporting units as follows: Financial Services in the amount of \$4.3 million, Consumer and Healthcare in the amount of \$7.3 million and High Tech and Manufacturing in the amount of \$34.4 million, using a relative fair value allocation method. Goodwill arising from this acquisition is deductible for income tax purposes and represents primarily the acquired capabilities and other benefits expected to result from combining the acquired operations with our existing operations.

On December 31, 2020, we acquired 100% of the outstanding equity interests in Enquero Inc, a California corporation, and certain affiliated entities in India, the Netherlands and Canada (collectively referred to as "Enquero") for total purchase consideration of \$148.8 million. This amount represents cash consideration of \$137.2 million, net of cash acquired of \$11.6 million. This acquisition increased the scale and depth of our data and analytics capabilities, enhancing our ability to accelerate the digital transformation journeys of our clients through cloud technologies and advanced data analytics. Goodwill arising from the acquisition amounting to \$87.9 million has been allocated among our three reporting units as follows: Financial Services in the amount of \$2.6 million, Consumer and Healthcare in the amount of \$22.5 million and High Tech and Manufacturing in the amount of \$62.7 million, using a relative fair value allocation method. Goodwill arising from this acquisition is not deductible for income tax purposes and represents primarily the acquired capabilities and other benefits expected to result from combining the acquired operations with our existing operations.

On October 5, 2020, we acquired 100% of the outstanding equity/limited liability company interests in SomethingDigital.Com LLC, a New York limited liability company, for total purchase consideration of \$57.5 million. This amount represents cash consideration of \$56.1 million, net of cash acquired of \$1.4 million. This acquisition supported our strategy to integrate experience and process innovation to help clients on their digital transformation journeys and

expanded on our existing experience capabilities to support end-to-end digital commerce solutions, both business-to-business and business-to-consumer. Additionally, this acquisition expanded our capabilities into Magento Commerce, which powers Adobe Commerce Cloud, and Shopify Plus, a cloud-based-ecommerce platform for high-volume merchants. Goodwill arising from the acquisition amounting to \$36.9 million has been allocated among two of our reporting units as follows: Consumer and Healthcare in the amount of \$30.4 million and High Tech and Manufacturing in the amount of \$6.6 million, using a relative fair value allocation method. Of the total goodwill arising from this acquisition, \$35.1 million is deductible for income tax purposes. The goodwill represents primarily the acquired capabilities and other benefits expected to result from combining the acquired operations with our existing operations.

On November 12, 2019, we acquired 100% of the outstanding equity/limited liability company interests in Rightpoint Consulting, LLC, an Illinois limited liability company, and certain affiliated entities in the United States and India (collectively referred to as "Rightpoint") for total purchase consideration of \$270.7 million. This amount includes cash consideration of \$268.2 million, net of cash acquired of \$2.5 million. This acquisition expanded our capabilities in improving customer experience and strengthens our reputation as a thought leader in this space. The securities purchase agreement provided certain of the selling equity holders the option to elect to either (a) receive 100% consideration in cash at the closing date for their limited liability company interests and vested options or (b) "roll over" and retain 25% of their Rightpoint limited liability company interests and vested options and receive consideration in cash at closing for the remaining 75% of their Rightpoint limited liability company interests and vested options. Certain selling equity holders elected to receive deferred, variable earnout consideration with an estimated value of \$21.5 million over the three-year rollover period, which is included in the purchase consideration. The amount of deferred consideration ultimately payable to the rollover sellers will be based on the future revenue multiple of the acquired business. Goodwill arising from the acquisition amounting to \$177.2 million has been allocated among our three reporting units as follows: Financial Services in the amount of \$17.0 million, Consumer and Healthcare in the amount of \$43.0 million and High Tech and Manufacturing in the amount of \$117.2 million, using a relative fair value allocation method. Of the total goodwill arising from this acquisition, \$91.9 million is deductible for income tax purposes. The goodwill primarily represents the acquired capabilities and other benefits expected to result from combining the acquired operations with our existing operations.

Critical Accounting Policies and Estimates

For a description of our critical accounting policies and estimates, see Note 2—"Summary of significant accounting policies" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above, as well as Part II, Item 7—"Management's Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates" and Note 2—"Summary of significant accounting policies" under Part IV, Item 15—"Exhibits and Financial Statement Schedules" in our Annual Report on Form 10-K for the year ended December 31, 2021. These have been no material changes to our critical accounting policies and estimates during the nine months ended September 30, 2022 from those described in our Annual Report on Form 10-K for the year ended December 31, 2021.

Due to rounding, the numbers presented in the tables included in this "Item 2—Management's Discussion and Analysis of Financial Condition and Results of Operations" may not add up precisely to the totals provided.

Results of Operations

The following table sets forth certain data from our consolidated statements of income for the three and nine months ended September 30, 2021 and 2022.

	Three months ended September 30,		Nine months ended September 30,		Percentage Change Increase/(Decrease)	
					Three months ended September 30,	Nine months ended Septe 30,
	2021	2022	2021	2022	2022 vs. 2021	2022 vs. 2021
	(dollars in millions)					
Data-Tech-AI	\$ 428.8	\$ 509.7	\$ 1,208.5	\$ 1,465.0	18.9 %	21
Digital Operations	586.9	601.3	1,741.4	1,803.6	2.4 %	3
Total net revenues	\$ 1,015.7	\$ 1,111.0	\$ 2,949.9	\$ 3,268.6	9.4 %	10
Cost of revenue	653.7	717.2	1,887.6	2,117.4	9.7 %	12
Gross profit	362.1	393.8	1,062.3	1,151.2	8.8 %	8
Gross profit margin	35.6 %	35.4 %	36.0 %	35.2 %		
Operating expenses						
Selling, general and administrative expenses	216.0	231.4	620.9	701.8	7.2 %	13
Amortization of acquired intangible assets	13.9	10.6	44.6	32.8	(23.7) %	(26)
Other operating (income) expense, net	(0.1)	20.9	(0.2)	42.2	NM*	N
Income from operations	132.3	130.8	397.1	374.4	(1.1) %	(5)
Income from operations as a percentage of net revenues	13.0 %	11.8 %	13.5 %	11.5 %		
Foreign exchange gains (losses), net	2.7	3.9	11.5	9.3	41.5 %	(19)
Interest income (expense), net	(12.8)	(13.4)	(38.2)	(36.7)	5.0 %	(3)
Other income (expense), net	1.5	(0.2)	9.0	(4.9)	(115.9) %	(154)
Income before income tax expense	123.7	121.1	379.4	342.1	(2.2) %	(9)
Income tax expense	21.4	25.2	83.0	78.4	18.2 %	(5)
Net income	\$ 102.4	\$ 95.8	\$ 296.4	\$ 263.7	(6.4) %	(11)
Net income as a percentage of net revenues	10.1 %	8.6 %	10.0 %	8.1 %		

*Not Meaningful

Three Months Ended September 30, 2022 Compared to the Three Months Ended September 30, 2021

Net revenues. Our net revenues were \$1,111.0 million in the third quarter of 2022, up \$95.3 million, or 9.4%, from \$1,015.7 million in the third quarter of 2021. The growth in our net revenues was primarily driven by strong demand for our Data-Tech-AI services, as well as continued steady performance in our Digital Operations services.

Adjusted for foreign exchange, primarily the impact of changes in the value of the Japanese yen, Australian dollar, euro and U.K. pound sterling against the U.S. dollar, our net revenues grew 12.3% in the third quarter of 2022 compared to the third quarter of 2021 on a constant currency¹ basis. We provide information about our revenue growth on a constant currency¹ basis so that our revenue may be viewed without the impact of foreign currency exchange rate fluctuations, thereby facilitating period-to-period comparisons of our business performance. Total net revenues on a constant currency¹ basis are calculated by restating current-period activity using the prior fiscal period's foreign currency exchange rates and adjusted for hedging gains/losses.

Our average headcount increased by 10.5% to approximately 116,400 in the third quarter of 2022 from approximately 105,300 in the third quarter of 2021.

	Three months ended September 30,		Percentage Change Increase/(Decrease) 2022 vs. 2021
	2021	2022	
	(dollars in millions)		
Data-Tech-AI	\$ 428.8	\$ 509.7	18.9 %
Digital Operations	586.9	601.3	2.4 %
Total net revenues	\$ 1,015.7	\$ 1,111.0	9.4 %

Net revenues from Data-Tech-AI services in the third quarter of 2022 were \$509.7 million, up \$80.9 million, or 18.9%, from \$428.8 million in the third quarter of 2021. This increase was largely driven by continued growth in our cloud-based data solutions and analytics solutions across our focus areas of supply chain management, sales and commercial, and risk management in the third quarter of 2022 compared to the third quarter of 2021.

Net revenues from Digital Operations services in the third quarter of 2022 were \$601.3 million, up \$14.4 million, or 2.4%, from \$586.9 million in the third quarter of 2021, primarily due to deal ramp-ups from existing contracts and recent wins.

Revenues by segment were as follows:

	Three months ended September 30,		Percentage Change Increase/(Decrease) 2022 vs. 2021
	2021	2022	
	(dollars in millions)		
Financial Services	\$ 258.5	\$ 303.8	17.5 %
Consumer and Healthcare	388.1	412.8	6.4 %
High Tech and Manufacturing	366.7	425.3	16.0 %
Total reportable segment	1,013.3	1,142.0	12.7 %
Others	2.4	(30.9)	NM*
Net revenues	1,015.7	1,111.0	9.4 %
Business held for sale	—	(3.9)	(100.0) %
Net revenues (excluding business held for sale)	\$ 1,015.7	\$ 1,107.1	9.0 %

*Not Meaningful

¹ Revenue growth on a constant currency basis is a non-GAAP measure and is calculated by restating current-period activity using the prior fiscal period's foreign currency exchange rates adjusted for hedging gains/losses in such period.

Net revenues from our Financial Services segment increased by 17.5% in the third quarter of 2022 compared to the third quarter of 2021, largely due to continued strong demand for our risk management services from both traditional banks and other financial services clients, leveraging data and analytics. Net revenues from our Consumer and Healthcare segment increased by 6.4% in the third quarter of 2022 compared to the third quarter of 2021, largely driven by Data-Tech-AI services, sales and commercial services and supply chain management engagements, as well as revenues from Hoodoo Digital, LLC, which we acquired in the fourth quarter of 2021. Net revenues from our High Tech and Manufacturing segment increased by 16.0% in the third quarter of 2022 compared to the third quarter of 2021, largely driven by sales and commercial services, supply chain management services and finance and accounting engagements with both new and existing clients, as well as revenues from Hoodoo Digital, LLC, which we acquired in the fourth quarter of 2021. Net revenues from "Others" in the table above primarily represents the impact of foreign exchange fluctuations, which is not allocated to our segments for management's internal reporting purposes. Net revenues from "Business held for sale" in the table above represents revenues from a business classified as held for sale with effect from April 1, 2022 as part of a series of actions we are taking to focus our business on emerging solutions where we see the greatest opportunities for growth and to deprioritize assets that no longer fit with our long-term strategy. For additional information, see Note 8—"Assets and liabilities held for sale" and Note 19—"Segment reporting" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above.

Cost of revenue. Cost of revenue was \$717.2 million in the third quarter of 2022, up \$63.5 million, or 9.7%, from \$653.7 million in the third quarter of 2021. The increase in cost of revenue in the third quarter of 2022 compared to the third quarter of 2021 was primarily due to (i) an increase in our operational headcount to support revenue growth, (ii) higher talent replacement costs as well as wage inflation and (iii) higher travel related expenses. This increase was partially offset by a decrease in depreciation and amortization expenses in the third quarter of 2022 compared to the third quarter of 2021.

Gross margin. Our gross margin decreased from 35.6% in the third quarter of 2021 to 35.4% in the third quarter of 2022. The decrease in gross margin was primarily due to higher personnel expenses, higher talent replacement costs, higher wage inflation and higher travel related expenses, partially offset by a decrease in depreciation and amortization expenses and increased productivity due to improved utilization of our Data-Tech-AI resources in the third quarter of 2022 compared to the third quarter of 2021.

Selling, general and administrative expenses (SG&A). SG&A expenses as a percentage of total net revenues decreased from 21.3% in the third quarter of 2021 to 20.8% in the third quarter of 2022. SG&A expenses were \$231.4 million in the third quarter of 2022, up \$15.5 million, or 7.2%, from the third quarter of 2021. The increase in SG&A expenses was primarily due to higher sales and marketing expenses, an increase in research and development costs related to cloud-based offerings and other prioritized service lines, increased travel related expenses and increased staffing as well as wage inflation in the third quarter of 2022 compared to the third quarter of 2021, partially offset by operating leverage.

Amortization of acquired intangibles. Amortization of acquired intangibles was \$10.6 million in the third quarter of 2022, down \$3.3 million, or 23.7%, from the third quarter of 2021. This decrease was primarily due to the completion of useful lives of intangibles acquired in prior periods, partially offset by amortization expense related to Hoodoo Digital, LLC, which we acquired in the fourth quarter of 2021.

Other operating (income) expense, net. Other operating expense (net of income) was \$20.9 million in the third quarter of 2022, compared to other operating income (net of expense) of \$0.1 million in the third quarter of 2021. The change in other operating income/expense was primarily due to an impairment charge of \$21.4 million in the third quarter of 2022 related to assets classified as held for sale, while no corresponding charge was recorded in the third quarter of 2021. For additional information, see Note 8—"Assets and liabilities held for sale" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above.

Income from operations. As a result of the foregoing factors, income from operations as a percentage of total net revenues decreased from 13.0% in the third quarter of 2021 to 11.8% in the third quarter of 2022. Income from operations decreased by \$1.4 million from \$132.3 million in the third quarter of 2021 to \$130.8 million in the third quarter of 2022, primarily due to higher SG&A expenses and an impairment charge on assets classified as held for sale, as discussed above, partially offset by lower amortization of acquired intangible assets in the third quarter of 2022 compared to the third quarter of 2021. For additional information, see Note 8—"Assets and liabilities held for sale" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above.

Foreign exchange gains (losses), net. We recorded a net foreign exchange gain of \$3.9 million in the third quarter of 2022 compared to \$2.7 million in the third quarter of 2021. The gain in the third quarter of 2022 resulted primarily from the depreciation of the Indian rupee against the U.S. dollar. The gain in the third quarter of 2021 resulted primarily from

gains on fair value hedges, partially offset by losses on remeasurement resulting from the appreciation of the Indian rupee against the U.S. dollar during the third quarter of 2021.

Interest income (expense), net. Our interest expense (net of interest income) was \$13.4 million in the third quarter of 2022, up \$0.6 million from \$12.8 million in the third quarter of 2021. Our interest expense was flat at \$14.8 million in the third quarters of both 2022 and 2021. Our interest income decreased from \$2.1 million in the third quarter of 2021 to \$1.4 million in the third quarter of 2022. This decrease was primarily due to lower interest income in India. The weighted average rate of interest on our debt, including the net impact of interest rate swaps, increased from 2.9% in the third quarter of 2021 to 3.0% in the third quarter of 2022.

Other income (expense), net. Our other expense (net of income) was \$0.2 million in the third quarter of 2022 compared to other income (net of expense) of \$1.5 million in the third quarter of 2021. This change was primarily due to losses on changes in the fair value of assets in our deferred compensation plan in the third quarter of 2022 compared to gains on changes in the fair value of assets in our deferred compensation plan the third quarter of 2021.

Income tax expense. Our income tax expense was \$25.2 million in the third quarter of 2022, up from \$21.4 million in the third quarter of 2021, representing an effective tax rate ("ETR") of 20.8% in the third quarter of 2022, up from 17.3% in the third quarter of 2021. The increase in our ETR was primarily due to a lower mix of benefits recorded in the third quarter of 2022 compared to the third quarter of 2021.

Net income. As a result of the foregoing factors, net income as a percentage of total net revenues was 8.6% in the third quarter of 2022, down from 10.1% in the third quarter of 2021. Net income decreased from \$102.4 million in the third quarter of 2021 to \$95.8 million in the third quarter of 2022, primarily due to an impairment charge on assets classified as held for sale, as discussed above. For additional information, see Note 8—"Assets and liabilities held for sale" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above.

Adjusted income from operations. Adjusted income from operations ("AOI") increased by \$19.9 million from \$168.9 million in the third quarter of 2021 to \$188.8 million in the third quarter of 2022. Our AOI margin increased from 16.6% in the third quarter of 2021 to 17.1% in the third quarter of 2022, largely due to growth-related operating leverage and the impact of our recent cost containment initiatives, partially offset by higher sales and marketing expenses and travel related expenses in the third quarter of 2022 compared to the third quarter of 2021. In calculating our AOI margin for the third quarter of 2022, we adjusted total net revenues to exclude revenues of \$3.9 million from the business designated as held for sale.

AOI is a non-GAAP measure and is not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and may be different from non-GAAP financial measures used by other companies. We believe that presenting AOI together with our reported results can provide useful supplemental information to our investors and management regarding financial and business trends relating to our financial condition and results of operations. A limitation of using AOI versus net income calculated in accordance with GAAP is that AOI excludes certain recurring costs and certain other charges, namely stock-based compensation and amortization of acquired intangibles. We compensate for this limitation by providing specific information on the GAAP amounts excluded from AOI.

We calculate AOI as net income, excluding (i) stock-based compensation, (ii) amortization and impairment of acquired intangible assets, (iii) acquisition-related expenses excluded in the period in which an acquisition is consummated, (iv) foreign exchange (gains)/losses, (v) any loss or gain from businesses held for sale, including impairment charges, (vi) restructuring expenses, (vii) interest (income) expense, and (viii) income tax expense, as we believe that our results after taking into account these adjustments more accurately reflect our ongoing operations. For additional information, see Note 19—"Segment reporting" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above.

During the second quarter of 2022, management approved a plan to divest a business within our Consumer and Healthcare segment. It is our intention to complete the sale of this business by June 2023. As a result, we have classified the assets and liabilities of this business as held for sale and have recorded net revenues and a loss of \$3.9 million and \$7.1 million, respectively, for the third quarter of 2022. We also recorded an impairment charge of \$21.4 million in the third quarter of 2022 on assets classified as held for sale. The loss and impairment charge were excluded from AOI in the third quarter of 2022. There was no corresponding loss or impairment charge in the third quarter of 2021, as this business was not designated as held for sale during such period. For additional information, see Note 8—"Assets and liabilities held for sale" and Note 19—"Segment reporting" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above.

The following table shows the reconciliation of AOI to net income, the most directly comparable GAAP measure, for the three months ended September 30, 2021 and 2022:

	Three months ended September 30,	
	2021	2022
	(dollars in millions)	
Net income	\$ 102.4	\$ 95.8
Foreign exchange (gains) losses, net	(2.7)	(3.9)
Interest (income) expense, net	12.8	13.4
Income tax expense	21.4	25.2
Stock-based compensation	21.5	19.2
Amortization and impairment of acquired intangible assets	13.7	10.5
Loss relating to business held for sale	—	7.1
Impairment charge on assets classified as held for sale	—	21.4
Adjusted income from operations	\$ 168.9	\$ 188.8

The following table sets forth our AOI by segment for the three months ended September 30, 2021 and 2022:

	Three months ended September 30,		Percentage Change Increase/(Decrease)
	2021	2022	2022 vs. 2021
	(dollars in millions)		
Financial Services	\$ 32.5	\$ 41.0	26.1 %
Consumer and Healthcare	63.7	49.6	(22.1) %
High Tech and Manufacturing	68.3	69.6	1.9 %
Total reportable segment	164.5	160.2	(2.6) %
Others	4.5	21.6	NM*
Total	168.9	181.8	7.6 %
Loss relating to business held for sale	—	7.1	100.0 %
Adjusted income from operations	\$ 168.9	\$ 188.8	11.8 %

*Not Meaningful

AOI of our Financial Services segment increased to \$41.0 million in the third quarter of 2022 from \$32.5 million in the third quarter of 2021, primarily due to higher revenues and improved efficiency, partially offset by higher talent replacement costs as well as wage inflation. AOI of our Consumer and Healthcare segment decreased to \$49.6 million in the third quarter of 2022 from \$63.7 million in the third quarter of 2021, largely due to higher sales costs, higher talent replacement costs and the impact of wage inflation, partially offset by higher revenues. AOI of our High Tech and Manufacturing segment increased to \$69.6 million in the third quarter of 2022 from \$68.3 million in the third quarter of 2021, primarily driven by higher revenues, partially offset by higher talent replacement costs as well as wage inflation. AOI for "Others" in the table above primarily represents the impact of foreign exchange fluctuations, adjustment of allowances for credit losses and over- or under-absorption of overheads, none of which is allocated to any individual segment for management's internal reporting purposes. AOI for "Business held for sale" in the table above primarily represents the loss attributable to a business classified as held for sale. See Note 19—"Segment reporting" and Note 8—"Assets and liabilities held for sale" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above.

Nine months ended September 30, 2022 Compared to the Nine months ended September 30, 2021

Net revenues. Our net revenues were \$3,268.6 million in the nine months ended September 30, 2022, up \$318.7 million, or 10.8%, from \$2,949.9 million in the nine months ended September 30, 2021. The growth in our net revenues was from both Data-Tech-AI and Digital Operations services.

Adjusted for foreign exchange, primarily the impact of changes in the value of the Japanese yen, Australian dollar, euro and U.K. pound sterling against the U.S. dollar, our net revenues grew 12.9% in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 on a constant currency² basis. Revenue growth on a constant currency² basis is a non-GAAP measure. We provide information about our revenue growth on a constant currency² basis so that our revenue may be viewed without the impact of foreign currency exchange rate fluctuations, thereby facilitating period-to-period comparisons of our business performance. Total net revenues on a constant currency² basis are calculated by restating current-period activity using the prior fiscal period's foreign currency exchange rates and adjusted for hedging gains/losses.

Our average headcount increased by 13.1% to approximately 114,800 in the nine months ended September 30, 2022 from approximately 101,500 in the nine months ended September 30, 2021.

	Nine months ended September 30,		Percentage Change
	2021	2022	Increase/(Decrease) 2022 vs. 2021
	(dollars in millions)		
Data-Tech-AI	\$ 1,208.5	\$ 1,465.0	21.2 %
Digital Operations	1,741.4	1,803.6	3.6 %
Total net revenues	\$ 2,949.9	\$ 3,268.6	10.8 %

Net revenues from Data-Tech-AI services in the nine months ended September 30, 2022 were \$1,465.0 million, up \$256.5 million, or 21.2%, from \$1,208.5 million in the nine months ended September 30, 2021. This increase was largely driven by continued growth in our cloud-based data solutions across our focus areas of supply chain management, sales and commercial, and risk management in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021.

Net revenues from Digital Operations services in the nine months ended September 30, 2022 were \$1,803.6 million, up \$62.2 million, or 3.6%, from \$1,741.4 million in the nine months ended September 30, 2021, primarily due to increased deal ramp-ups from existing contracts and new wins.

² Revenue growth on a constant currency basis is a non-GAAP measure and is calculated by restating current-period activity using the prior fiscal period's foreign currency exchange rates adjusted for hedging gains/losses in such period.

Revenues by segment were as follows:

	Nine months ended September 30,		Percentage Change
	2021	2022	Increase/(Decrease) 2022 vs. 2021
	(dollars in millions)		
Financial Services	\$ 750.6	\$ 872.6	16.3 %
Consumer and Healthcare	1,101.2	1,223.3	11.1 %
High Tech and Manufacturing	1,081.8	1,225.7	13.3 %
Total reportable segment	2,933.5	3,321.6	13.2 %
Others	16.4	(53.0)	NM*
Net revenues	2,949.9	3,268.6	10.8 %
Business held for sale	—	(8.8)	(100.0) %
Net revenues (excluding business held for sale)	\$ 2,949.9	\$ 3,259.8	10.5 %

*Not Meaningful

Net revenues from our Financial Services segment increased by 16.3% in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021, largely due to continued strong demand for our risk management services from both traditional banks and other financial services clients, leveraging data and analytics. Net revenues from our Consumer and Healthcare segment increased by 11.1% in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021, largely driven by sales and commercial services and supply chain management engagements as well as revenues from Hoodoo Digital, LLC, which we acquired in the fourth quarter of 2021. Net revenues from our High Tech and Manufacturing segment increased by 13.3% in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021, largely driven by supply chain management and finance and accounting engagements with both new and existing clients, as well as revenues from Hoodoo Digital, LLC, which we acquired in the fourth quarter of 2021. Net revenues from "Others" primarily represents the impact of foreign exchange fluctuations, which is not allocated to our segments for management's internal reporting purposes. Net revenues from "Business held for sale" in the table above represents revenues from a business classified as held for sale with effect from April 1, 2022 as part of a series of actions we are taking to focus our business on emerging solutions where we see the greatest opportunities for growth and to deprioritize assets that no longer fit with our long-term strategy. For additional information, see Note 8—"Assets and liabilities held for sale" and Note 19—"Segment reporting" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above.

Cost of revenue. Cost of revenue was \$2,117.4 million in the nine months ended September 30, 2022, up \$229.8 million, or 12.2%, from \$1,887.6 million in the nine months ended September 30, 2021. The increase in our cost of revenue in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 was primarily due to (i) an increase in our operational headcount to support revenue growth, (ii) higher talent replacement cost as well as wage inflation, and (iii) higher travel related expenses. This increase was partially offset by (i) lower depreciation and amortization expense, (ii) lower facilities maintenance expenses and (iii) lower communication expenses. We also recorded an employee severance charge as part of the restructuring we undertook in the nine months ended September 30, 2022, while no corresponding charge was recorded in the nine months ended September 30, 2021. For additional information, see Note 25—"Restructuring" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above.

Gross margin. Our gross margin decreased from 36.0% in the nine months ended September 30, 2021 to 35.2% in the nine months ended September 30, 2022. Excluding the impact of an employee severance charge of \$8.4 million, gross margin was 35.5% in the nine months ended September 30, 2022. The decrease in gross margin, excluding the impact of an employee severance charge, was primarily due to higher personnel expenses, higher talent replacement costs and wage inflation, and higher travel related expenses in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021.

Selling, general and administrative expenses (SG&A). SG&A expenses as a percentage of total net revenues increased from 21.0% in the nine months ended September 30, 2021 to 21.5% in the nine months ended September 30, 2022. Excluding the impact of an employee severance charge of \$8.7 million, SG&A expenses as a percentage of total net revenues were 21.2% in the nine months ended September 30, 2022. SG&A expenses were \$701.8 million in the nine months ended September 30, 2022, up \$81.0 million from \$620.9 million in the nine months ended September 30, 2021.

The increase in SG&A expenses, excluding the impact of an employee severance charge, was primarily due to higher sales and marketing expenses, increased investments to support increased revenues, an increase in research and development costs related to cloud-based offerings and other prioritized service lines, travel related expenses and increased staffing, as well as wage inflation in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021, partially offset by operational leverage.

Amortization of acquired intangibles. Amortization of acquired intangibles was \$32.8 million in the nine months ended September 30, 2022, down \$11.8 million, or 26.5%, from the nine months ended September 30, 2021. This decrease was primarily due to the completion of the useful lives of intangibles acquired in prior periods, partially offset by amortization expense related to Hoodoo Digital, LLC, which we acquired in the fourth quarter of 2021.

Other operating (income) expense, net. Other operating expense (net of income) was \$42.2 million in the nine months ended September 30, 2022 compared to other operating income (net of expense) of \$0.2 million in the nine months ended September 30, 2021. The change in other operating expense/income was due to a \$20.3 million write-down related to the abandonment of various office premises and a \$1.4 million write-down related to tangible assets, both of which were taken as part of a restructuring in the nine months ended September 30, 2022. We also recorded an impairment charge of \$21.4 million in the nine months ended September 30, 2022 related to assets classified as held for sale, while no corresponding charges were recorded in the nine months ended September 30, 2021. For additional information, see Note 8—“Assets and liabilities held for sale” and Note 25—“Restructuring” under Part I, Item 1—“Unaudited Consolidated Financial Statements” above.

Income from operations. As a result of the foregoing factors, income from operations as a percentage of total net revenues decreased from 13.5% in the nine months ended September 30, 2021 to 11.5% in the nine months ended September 30, 2022. Income from operations decreased by \$22.7 million from \$397.1 million in the nine months ended September 30, 2021 to \$374.4 million in the nine months ended September 30, 2022, primarily due to an impairment charge on assets classified as held for sale and the restructuring discussed above. For additional information, see Note 8—“Assets and liabilities held for sale” and Note 25—“Restructuring” under Part I, Item 1—“Unaudited Consolidated Financial Statements” above.

Foreign exchange gains (losses), net. We recorded a net foreign exchange gain of \$9.3 million in the nine months ended September 30, 2022, compared to \$11.5 million in the nine months ended September 30, 2021. The gain in each of the nine month periods ended September 30, 2022 and 2021 resulted primarily from the depreciation of the Indian rupee against the U.S. dollar.

Interest income (expense), net. Our interest expense (net of interest income) was \$36.7 million in the nine months ended September 30, 2022, down \$1.5 million from \$38.2 million in the nine months ended September 30, 2021, primarily due to a \$2.0 million decrease in interest expense, offset by a \$0.5 million decrease in interest income. The decrease in interest expense was largely due to the repayment of our \$350 million aggregate principal amount of 3.70% senior notes issued in March 2017, partially offset by a higher outstanding balance and higher average London Interbank Offered Rate (“LIBOR”)-based rate on our revolving credit facility in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021, which we discuss in the section titled “Liquidity and Capital Resources—Financial Condition” below. The weighted average rate of interest on our debt, including the net impact of interest rate swaps, was 2.9% in each of the nine months ended September 30, 2022 and 2021.

Other income (expense), net. Our other expense (net of income) was \$4.9 million in the nine months ended September 30, 2022 compared to other income (net of expense) of \$9.0 million in the nine months ended September 30, 2021. This change was largely attributable to losses on changes in the fair value of assets in our deferred compensation plan in the nine months ended September 30, 2022 compared to gains on changes in the fair value of assets in our deferred compensation plan in the nine months ended September 30, 2021 and the settlement of certain pre-GE divestiture related tax liabilities in the nine months ended September 30, 2021, for which we were indemnified by GE.

Income tax expense. Our income tax expense was \$78.4 million in the nine months ended September 30, 2022, down from \$83.0 million in the nine months ended September 30, 2021, due to lower pre-tax income, representing an ETR of 22.9% in the nine months ended September 30, 2022, up from 21.9% in the nine months ended September 30, 2021. The increase in our ETR was primarily due to a lower mix of benefits recorded in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021.

Net income. As a result of the foregoing factors, net income as a percentage of total net revenues was 8.1% in the nine months ended September 30, 2022, down from 10.0% in the nine months ended September 30, 2021. Net income decreased by \$32.7 million from \$296.4 million in the nine months ended September 30, 2021 to \$263.7 million in the nine months ended September 30, 2022, primarily due to lower gross margins, an impairment charge on assets classified

as held for sale and the restructuring discussed above. For additional information, see note 8—"Assets and liabilities held for sale" and Note 25—"Restructuring" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above.

Adjusted income from operations. Adjusted income from operations ("AOI") increased by \$23.0 million from \$508.6 million in the nine months ended September 30, 2021 to \$531.6 million in the nine months ended September 30, 2022. Our AOI margin decreased to 16.3% in the nine months ended September 30, 2022 from 17.2% in the nine months ended September 30, 2021. The decrease in AOI margin was due to lower gross margins, higher sales and marketing expenses, an increase in investments in research and development related to cloud-based offerings and other prioritized service lines and increased travel related expenses in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. In calculating our AOI margin for the nine months ended September 30, 2022, we adjusted total net revenues to exclude revenues of \$8.8 million from the business designated as held for sale.

AOI is a non-GAAP measure and is not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and may be different from non-GAAP financial measures used by other companies. We believe that presenting AOI together with our reported results can provide useful supplemental information to our investors and management regarding financial and business trends relating to our financial condition and results of operations. A limitation of using AOI versus net income calculated in accordance with GAAP is that AOI excludes certain recurring costs and certain other charges, namely stock-based compensation and amortization of acquired intangibles. We compensate for this limitation by providing specific information on the GAAP amounts excluded from AOI.

We calculate AOI as net income, excluding (i) stock-based compensation, (ii) amortization and impairment of acquired intangible assets, (iii) acquisition-related expenses excluded in the period in which an acquisition is consummated, (iv) foreign exchange (gain)/loss, (v) restructuring expenses, (vi) any loss or gain on businesses held for sale, including impairment charges, (vii) interest (income) expense, and (viii) income tax expense, as we believe that our results after taking into account these adjustments more accurately reflect our ongoing operations. For additional information, see Note 19—"Segment reporting" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above.

During the nine months ended September 30, 2022, we carried out certain restructuring activities in line with our long-term strategy to implement a flexible, hybrid global delivery model that incorporates a mix of offshore, onshore, near shore, and remote working. As a result, we determined that certain leases and employee roles were unnecessary. Accordingly, we took a restructuring charge of \$38.8 million, which was excluded from AOI in the nine months ended September 30, 2022. No corresponding charge was recorded in the nine months ended September 30, 2021. For additional information, see Note 25—"Restructuring" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above.

During the nine months ended September 30, 2022, management approved a plan to divest a business within our Consumer and Healthcare segment. It is our intention to complete the sale of this business by June 2023. As a result, we have classified the assets and liabilities of this business as held for sale and have recorded net revenues and loss of \$8.8 million and \$14.3 million, respectively, for the nine months ended September 30, 2022. We also recorded an impairment charge of \$21.4 million on assets classified as held for sale for the nine months ended September 30, 2022. The loss and impairment charge were excluded from AOI in the nine months ended September 30, 2022, and there were no corresponding loss and impairment charge to exclude in the nine months ended September 30, 2021, as this business was not designated as held for sale during such period. For additional information, see Note 8—"Assets and liabilities held for sale" and Note 19—"Segment reporting" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above.

The following table shows the reconciliation of AOI to net income, the most directly comparable GAAP measure for the nine months ended September 30, 2021 and 2022:

	Nine months ended September 30,	
	2021	2022
	(dollars in millions)	
Net income	\$ 296.4	\$ 263.7
Foreign exchange (gains) losses, net	(11.5)	(9.3)
Interest (income) expense, net	38.2	36.7
Income tax expense	83.0	78.4
Stock-based compensation	58.6	54.9
Amortization and impairment of acquired intangible assets	44.0	32.7
Restructuring expense	—	38.8
Loss relating to business held for sale	—	14.3
Impairment charge on assets classified as held for sale	—	21.4
Adjusted income from operations	\$ 508.6	\$ 531.6

The following table sets forth our AOI by segment for the nine months ended September 30, 2021 and 2022:

	Nine months ended September 30,		Percentage Change Increase/(Decrease) 2022 vs. 2021
	2021	2022	
	(dollars in millions)		
Financial Services	\$ 99.0	\$ 102.7	3.8 %
Consumer and Healthcare	184.6	158.3	(14.3) %
High Tech and Manufacturing	203.9	207.9	1.9 %
Total reportable segment	487.5	468.9	(3.8) %
Others	21.1	48.5	129.8 %
Total	508.6	517.3	1.7 %
Loss relating to business held for sale	—	14.3	100.0 %
Adjusted income from operations	\$ 508.6	\$ 531.6	4.5 %

AOI of our Financial Services segment increased to \$102.7 million in the nine months ended September 30, 2022 from \$99.0 million in the nine months ended September 30, 2021, primarily due to higher revenues and improved efficiency, partially offset by higher talent replacement costs as well as wage inflation in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. AOI of our Consumer and Healthcare segment decreased from \$184.6 million in the nine months ended September 30, 2021 to \$158.3 million in the nine months ended September 30, 2022, largely due to higher sales costs, higher talent replacement costs and the impact of wage inflation, partially offset by higher revenues in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. AOI of our High Tech and Manufacturing segment increased to \$207.9 million in the nine months ended September 30, 2022 from \$203.9 million in the nine months ended September 30, 2021 due to higher revenues, partially offset by higher talent replacement costs as well as wage inflation. AOI for "Others" in the table above primarily represents the impact of foreign exchange fluctuations, adjustment of allowances for credit losses and over- or under-absorption of overheads, none of which is allocated to any individual segment for management's internal reporting purposes. AOI for "Business held for sale" in the table above primarily represents the loss attributable to a business classified as held for sale. See Note 8—"Assets and liabilities held for sale" and Note 19—"Segment reporting" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above.

Liquidity and Capital Resources

Overview

Information about our financial position as of December 31, 2021 and September 30, 2022 is presented below:

	As of December 31, 2021		As of September 30, 2022		Percentage Change Increase/(Decrease) 2022 vs. 2021
	(dollars in millions)				
Cash and cash equivalents	\$	899.5	\$	518.7	(42.3)%
Short-term borrowings		—		200.0	NM*
Long-term debt due within one year		383.4		535.1	39.6%
Long-term debt other than the current portion		1,272.5		746.6	(41.3)%
Genpact Limited total shareholders' equity	\$	1,897.1	\$	1,731.8	(8.7)%

*Not Meaningful

Financial Condition

We have historically financed our operations and our expansion, including acquisitions, with cash from operations and borrowing facilities.

On February 9, 2021, our board of directors approved a 10% increase in our quarterly cash dividend to \$0.1075 per share, up from \$0.0975 per share in 2020, representing an annual dividend of \$0.43 per common share, up from \$0.39 per share in 2020, payable to holders of our common shares. On March 19, 2021, June 23, 2021 and September 24, 2021, we paid a dividend of \$0.1075 per share, amounting to \$20.1 million, \$20.1 million and \$20.2 million in the aggregate, to shareholders of record as of March 10, 2021, June 11, 2021 and September 10, 2021, respectively.

On February 10, 2022, our board of directors approved a 16% increase in our quarterly cash dividend to \$0.125 per share, up from \$0.1075 per share in 2021, representing a planned annual dividend of \$0.50 per common share, up from \$0.43 per share in 2021, payable to holders of our common shares. On March 23, 2022, June 24, 2022 and September 23, 2022, we paid a dividend of \$0.125 per share, amounting to \$23.1 million, \$22.9 million and \$22.9 million in the aggregate, to shareholders of record as of March 10, 2022, June 10, 2022 and September 9, 2022, respectively.

As of September 30, 2022, \$514.5 million of our \$518.7 million in cash and cash equivalents was held by our foreign (non-Bermuda) subsidiaries. \$3.3 million of this cash was held by foreign subsidiaries for which we expect to incur and have accrued a deferred tax liability on the repatriation of \$9.6 million of retained earnings. \$511.2 million of the cash and cash equivalents is held by foreign subsidiaries in jurisdictions where no tax is expected to be imposed upon repatriation of retained earnings or is being indefinitely reinvested.

The total authorization under our existing share repurchase program is \$1,750.0 million, of which \$156.9 million remained available as of September 30, 2022. Since our share repurchase program was initially authorized in 2015, we have repurchased 51,454,121 of our common shares at an average price of \$30.96 per share, for an aggregate purchase price of \$1,593.1 million.

During the nine months ended September 30, 2022, we repurchased 4,067,044 of our common shares on the open market at a weighted average price of \$44.75 per share for an aggregate cash amount of \$182.0 million. During the nine months ended September 30, 2021, we repurchased 3,592,409 of our common shares on the open market at a weighted average price of \$40.96 per share for an aggregate cash amount of \$147.2 million. All repurchased shares have been retired.

For additional information, see Note 17—"Capital stock" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above.

We expect that for the next twelve months and for the foreseeable future our cash from operations, cash reserves and debt capacity will be sufficient to finance our operations, our growth and expansion plans, dividend payments and additional share repurchases we may make under our share repurchase program. However, there is no assurance that the

impacts of the COVID-19 pandemic we have experienced to date, and any future impact we may experience, will not have an adverse effect on our cash flows. In addition, we may raise additional funds through public or private debt or equity financing. Our working capital needs are primarily to finance our payroll and other administrative and information technology expenses in advance of the receipt of accounts receivable. Our primary capital requirements include opening new delivery centers, expanding existing operations to support our growth, financing acquisitions and enhancing capabilities, including building certain digital solutions.

Cash flows from operating, investing and financing activities, as reflected in our consolidated statements of cash flows, are summarized in the following table:

	Nine months ended September 30,		Percentage Change
	2021	2022	Increase/(Decrease) 2022 vs. 2021
	(dollars in millions)		
Net cash provided by/ (used for):			
Operating activities	\$ 447.5	\$ 214.0	(52.2) %
Investing activities	(37.3)	(37.3)	— %
Financing activities	(151.1)	(471.2)	211.8 %
Net increase/(decrease) in cash and cash equivalents	\$ 259.1	\$ (294.4)	(213.6) %

Cash flows provided by operating activities. Net cash provided by operating activities was \$214.0 million in the nine months ended September 30, 2022 compared to \$447.5 million in the nine months ended September 30, 2021. The decrease in cash provided by operating activities was primarily due to (i) a \$216.2 million decrease in operating assets and liabilities driven by increased investment in accounts receivable, higher tax payments (net of tax refunds), and higher employee and vendor related payments in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 and (ii) a \$32.7 million decrease in net income in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. The decrease was offset by a \$16.0 million increase in non-cash expense, primarily due to (i) a \$20.3 million write-down of operating lease right-of-use assets and other assets as part of our restructuring and (ii) a \$21.4 million impairment charge on assets classified as held for sale, partially offset by a \$26.1 million reduction in depreciation and amortization expense in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021.

Cash flows used for investing activities. Our net cash used for investing activities was flat at \$37.3 million in both the nine months ended September 30, 2022 and 2021. Cash used for payments (net of sales proceeds) for the purchase of property, plant and equipment and acquired/internally generated intangible assets was \$7.5 million higher in the nine months ended September 30, 2022 than in the nine months ended September 30, 2021. Cash used for business combinations was \$6.6 million in the nine months ended September 30, 2021, compared to a refund of \$0.1 million in the nine months September 30, 2022.

Cash flows used for financing activities. Our net cash used for financing activities was \$471.2 million in the nine months ended September 30, 2022 compared to \$151.1 million in the nine months ended September 30, 2021. This change was primarily due to (i) the repayment of borrowings (net of proceeds) of \$175.5 million in the nine months ended September 30, 2022 compared to proceeds from borrowings (net of repayment) of \$74.5 million in the nine months ended September 30, 2021, (ii) an increase in payments for the net settlement of stock-based awards, amounting to \$44.9 million in the nine months ended September 30, 2022 compared to \$33.5 million in the nine months ended September 30, 2021, (iii) a decrease in proceeds from the issuance of common shares under our stock-based compensation plans, amounting to \$13.0 million in the nine months ended September 30, 2022 compared to \$29.8 million in the nine months ended September 30, 2021, (iv) higher dividend payments, amounting to \$68.9 million in the nine months ended September 30, 2022 compared to \$60.5 million in the nine months ended September 30, 2021, and (v) higher payments for stock purchased and retired (including payments of expenses related to stock repurchase activity), amounting to \$182.1 million in the nine months ended September 30, 2022 compared to \$147.2 million in the nine months ended September 30, 2021.

Financing Arrangements

As of December 31, 2021 and September 30, 2022, our outstanding term loan, net of debt amortization expense of \$0.7 million and \$0.4 million, respectively, was \$560.3 million and \$535.1 million, respectively. We also have fund-based and non-fund based credit facilities with banks, which are available for operational requirements in the form of overdrafts, letters of credit, guarantees and short-term loans. As of December 31, 2021 and September 30, 2022, the limits available under such facilities were \$24.7 million and \$22.9 million, respectively, of which \$5.8 million and \$5.0 million, respectively, was utilized, constituting non-funded drawdown. As of December 31, 2021 and September 30, 2022, a total of \$2.0 million and \$202.7 million, respectively, of our revolving credit facility was utilized, of which \$0 million and \$200.0 million, respectively, constituted funded drawdown and \$2.0 million and \$2.7 million, respectively, constituted non-funded drawdown. Our outstanding term loan and revolving credit facility expire on August 8, 2023. We are in the process of refinancing our term loan and revolving credit facility, and are currently in negotiation with various financial institutions and expect to close the refinancing in the fourth quarter of 2022.

Genpact Luxembourg S.à r.l. ("Genpact Luxembourg"), a wholly-owned subsidiary of the Company, issued \$350 million aggregate principal amount of 3.70% senior notes in March 2017 (the "2017 Senior Notes"). The 2017 Senior Notes were fully guaranteed by the Company and Genpact USA, Inc. The total debt issuance cost of \$2.6 million incurred in connection with the 2017 Senior Notes offering was amortized over the life of the notes as additional interest expense. As of December 31, 2021 and September 30, 2022, the amount outstanding under the 2017 Senior Notes, net of debt amortization expense of \$0.1 million and \$0 million, respectively, was \$349.9 million and \$0 million, respectively. On April 1, 2022, the maturity date of 2017 Senior Notes, the 2017 Senior Notes were fully repaid.

Genpact Luxembourg issued \$400 million aggregate principal amount of 3.375% senior notes in November 2019 (the "2019 Senior Notes"). The 2019 Senior Notes are fully guaranteed by the Company and Genpact USA, Inc. The total debt issuance cost of \$2.9 million incurred in connection with the 2019 Senior Notes offering is being amortized over the life of the notes as additional interest expense. As of December 31, 2021 and September 30, 2022, the amount outstanding under the 2019 Senior Notes, net of debt amortization expense of \$1.7 million and \$1.3 million, was \$398.3 million and \$398.7 million, respectively, which is payable on December 1, 2024.

Genpact Luxembourg and Genpact USA, Inc. ("Genpact USA"), both wholly-owned subsidiaries of the Company, co-issued \$350 million aggregate principal amount of 1.750% senior notes in March 2021 (the "2021 Senior Notes"). The 2021 Senior Notes are fully guaranteed by the Company. The total debt issuance cost of \$3.0 million incurred in connection with the 2021 Senior Notes offering is being amortized over the life of the notes as additional interest expense. As of December 31, 2021 and September 30, 2022, the amount outstanding under the 2021 Senior Notes, net of debt amortization expense of \$2.6 million and \$2.1 million, respectively, was \$347.4 million and \$347.9 million, respectively, which is payable on April 10, 2026.

We pay interest on (i) the 2019 Senior Notes semi-annually in arrears on June 1 and December 1 of each year, and (ii) the 2021 Senior Notes semi-annually in arrears on April 10 and October 10 of each year, ending on the maturity dates of December 1, 2024 and April 10, 2026, respectively.

For additional information, see Notes 11 and 12—"Short-term borrowings" and "Long-term debt" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above.

We use a revolving accounts receivable-based facility for managing our cash flows. As part of this arrangement, accounts receivable sold under this facility are de-recognized upon sale along with the related allowances, if any. As of December 31, 2021 and September 30, 2022, we have a revolving accounts receivable-based facility of \$100.0 million permitting us to sell accounts receivable to banks on a non-recourse basis in the ordinary course of business. The aggregate maximum capacity utilized at any time during the period ended December 31, 2021 and September 30, 2022 was \$7.1 million and \$67.4 million, respectively. The principal amount outstanding against this facility as of December 31, 2021 and September 30, 2022 was \$0 million and \$27.3 million, respectively. The cost of factoring accounts receivable sold under this facility during the three and nine months ended September 30, 2021 and 2022 was \$0 million and \$0.1 million, respectively, and \$0 million and \$0.3 million, respectively.

Off-Balance Sheet Arrangements

Our off-balance sheet arrangements consist of foreign exchange contracts. For additional information, see Part I, Item 1A—"Risk Factors"—"Currency exchange rate fluctuations in various currencies in which we do business, especially the Indian rupee, the euro and the U.S. dollar, could have a material adverse effect on our business, results of operations and financial condition" in our Annual Report on Form 10-K for the year ended December 31, 2021, and Note 6—"Derivative financial instruments" under Part I, Item 1—"Unaudited Consolidated Financial Statements" above.

Other Liquidity and Capital Resources Information

As of December 31, 2021 and September 30, 2022, we have purchase commitments, net of capital advances, of \$13.3 million and \$22.4 million, respectively, to be paid in respect of such purchases over the next year. For additional information, see Note 24—“Commitments and contingencies” under Part I, Item 1—“Unaudited Consolidated Financial Statements” above and Part II, Item 7—“Management’s Discussion and Analysis of Financial Condition and Results of Operations”—“Other Liquidity and Capital Resources Information” in our Annual Report on Form 10-K for the year ended December 31, 2021.

As of December 31, 2021 and September 30, 2022, we have operating and finance lease commitments of \$420.6 million and \$329.6 million, respectively, to be paid over the lease terms. For additional information, see Part II, Item 7—“Management’s Discussion and Analysis of Financial Condition and Results of Operations”—“Other Liquidity and Capital Resources Information” in our Annual Report on Form 10-K for the year ended December 31, 2021.

Supplemental Guarantor Financial Information

As discussed in Note 12, "Long-term debt," under Part I, Item 1—"Unaudited Consolidated Financial Statements" above, Genpact Luxembourg, a wholly-owned subsidiary of the Company, issued the 2019 Senior Notes, and Genpact Luxembourg and Genpact USA co-issued the 2021 Senior Notes. As of September 30, 2022, the outstanding balance for the 2019 Senior Notes and the 2021 Senior Notes (collectively, the "Senior Notes") was \$398.7 million and \$347.9 million, respectively. Each series of Senior Notes is fully and unconditionally guaranteed by the Company. The 2019 Senior Notes are fully and unconditionally guaranteed by Genpact USA. Our other subsidiaries do not guarantee the Senior Notes (such subsidiaries are referred to as the "non-Guarantors").

The Company (with respect to all series of Senior Notes) and Genpact USA (with respect to the 2019 Senior Notes) have fully and unconditionally guaranteed (i) that the payment of the principal, premium, if any, and interest on the Senior Notes shall be promptly paid in full when due, whether at stated maturity of the Senior Notes, by acceleration, redemption or otherwise, and that the payment of interest on the overdue principal and interest on the Senior Notes, if any, if lawful, and all other obligations of the applicable issuer or issuers of the Senior Notes, respectively, to the holders of the Senior Notes or the trustee under the Senior Notes shall be promptly paid in full or performed, and (ii) in case of any extension of time of payment or renewal of any Senior Notes or any of such other obligations, that the same shall be promptly paid in full when due or performed in accordance with the terms of the extension or renewal, whether at stated maturity, by acceleration or otherwise. With respect to the 2019 Senior Notes, failing payment by Genpact Luxembourg when due of any amount so guaranteed or any performance so guaranteed for whatever reason, the Company and Genpact USA shall be obligated to pay the same immediately. With respect to the 2021 Senior Notes, failing payment by Genpact Luxembourg or Genpact USA when due of any amount so guaranteed or any performance so guaranteed for whatever reason, the Company shall be obligated to pay the same immediately. The Company and Genpact USA have agreed that the guarantees described above are guarantees of payment of the Senior Notes and not guarantees of collection.

The following tables present summarized financial information for Genpact Luxembourg, Genpact USA and the Company (collectively, the "Debt Issuers and Guarantors") on a combined basis after elimination of (i) intercompany transactions and balances among the Debt Issuers and Guarantors and (ii) equity in earnings from and investments in the non-Guarantors.

Summarized Statements of Income	Year ended			Nine months ended
	December 31, 2021	(dollars in millions)		September 30, 2022
Net revenues	\$	214.2	\$	109.5
Gross profit		214.2		109.5
Net income		102.7		52.7

Below is a summary of transactions with non-Guarantors included in the summarized statement of income above:

	Year ended			Nine months ended
	December 31, 2021	(dollars in millions)		September 30, 2022
Royalty income	\$	4.4	\$	—
Revenue from services		209.8		109.5
Interest income (expense), net		33.0		15.9
Other cost, net		17.7		(1.6)

Summarized Balance Sheets	As of		As of	
	December 31, 2021		September 30, 2022	
	(dollars in millions)			
Assets				
Current assets	\$	2,257.8	\$	2,154.9
Non-current assets		457.5		172.2
Liabilities				
Current liabilities	\$	3,758.5	\$	4,104.9
Non-current liabilities		1,777.6		1,246.8

Below is a summary of the balances with non-Guarantors included in the summarized balance sheets above:

	As of		As of	
	December 31, 2021		September 30, 2022	
	(dollars in millions)			
Assets				
Current assets				
Accounts receivable, net	\$	211.3	\$	42.8
Loans receivable		1,535.5		1,460.5
Investment in debentures/bonds		—		196.1
Others		410.1		395.8
Non-current assets				
Investment in debentures/bonds	\$	296.1	\$	—
Others		31.5		70.4
Liabilities				
Current liabilities				
Loans payable	\$	2,431.2	\$	2,767.6
Others		914.0		582.3
Non-Current liabilities				
Loans payable	\$	500.0	\$	500.0

The Senior Notes and the related guarantees rank pari passu in right of payment with all senior and unsecured debt of the Debt Issuers and Guarantors and rank senior in right of payment to all of the Debt Issuers' and Guarantors' future subordinated debt. The Senior Notes are effectively subordinated to all of the Debt Issuers' and Guarantors' existing and future secured debt to the extent of the value of the assets securing such debt. The Senior Notes are structurally subordinated to all of the existing and future debt and other liabilities of the non-Guarantors, including the liabilities of certain subsidiaries pursuant to our senior credit facility. The non-Guarantors are separate and distinct legal entities and have no obligation, contingent or otherwise, to pay any amounts due under the Senior Notes or to make the funds available to pay those amounts, whether by dividend, distribution, loan or other payment. Any right that the Debt Issuers and Guarantors have, to receive any assets of any of the non-Guarantors upon the insolvency, liquidation, reorganization, dissolution or other winding-up of any non-Guarantor, all of that non-Guarantor's creditors (including trade creditors) would be entitled to payment in full out of that non-Guarantor's assets before the holders of the Senior Notes would be entitled to any payment. Claims of holders of the Senior Notes are structurally subordinated to the liabilities of certain non-Guarantors pursuant to their liabilities under our senior credit facility.

Recent Accounting Pronouncements

For a description of recent accounting pronouncements, see Note 2(n)—“Recently issued accounting pronouncements” under Item 1—“Unaudited Consolidated Financial Statements” above and Part II, Item 7—“Management’s Discussion and Analysis of Financial Condition and Results of Operations”—“Critical Accounting Policies and Estimates” in our Annual Report on Form 10-K for the year ended December 31, 2021.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to interest rate risk arising from changes in interest rates on the floating rate indebtedness under our term loan and revolving credit facility and the Senior Notes. Borrowings under our term loan and revolving credit facility bear interest at floating rates based on LIBOR, but in no event less than the floor rate of 0.0% plus an applicable margin. The interest rate on our Senior Notes is subject to adjustment based on the ratings assigned to our debt by Moody’s Investors Service, Inc. and Standard & Poor’s Rating Services, Inc. from time to time. A decline in such ratings could result in an increase of up to 2% in the rate of interest on the Senior Notes. Accordingly, fluctuations in market interest rates or a decline in ratings may increase or decrease our interest expense which would, in turn, increase or decrease our net income and cash flow.

We manage a portion of our interest rate risk related to floating rate indebtedness by entering into interest rate swaps under which we receive floating rate payments based on the greater of LIBOR and the floor rate under our term loan and make payments based on a fixed rate. As of September 30, 2022, we were party to interest rate swaps covering a total notional amount of \$439 million. Under these swap agreements, the rate that we pay to banks in exchange for LIBOR ranges between 0.38% and 2.65%.

We executed a treasury rate lock agreement covering \$350 million in connection with future interest payments to be made on our 2021 Senior Notes, and the treasury rate lock agreement was designated as a cash flow hedge. The treasury rate lock agreement was terminated on March 23, 2021, and a deferred gain was recorded in accumulated other comprehensive income and is being amortized to interest expense over the life of the 2021 Senior Notes. The remaining gain to be amortized related to the treasury rate lock agreement as of September 30, 2022 was \$0.6 million.

For a discussion of our market risk associated with foreign currency risk, interest rate risk and credit risk, see Part II, Item 7A—“Quantitative and Qualitative Disclosures about Market Risk” in our Annual Report on Form 10-K for the year ended December 31, 2021.

Item 4. Controls and Procedures***Evaluation of Disclosure Controls and Procedures***

Disclosure controls and procedures are the Company's controls and other procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 (the "Exchange Act") is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's Chief Executive Officer along with the Company's Chief Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures pursuant to Exchange Act Rule 13a-15(b). Based upon that evaluation, the Company's Chief Executive Officer along with the Company's Chief Financial Officer concluded that the Company's disclosure controls and procedures are effective in timely alerting them to material information relating to the Company (including its consolidated subsidiaries) required to be included in the Company's periodic SEC filings.

Changes in Internal Control over Financial Reporting

There were no changes in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarterly period ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

There are no legal proceedings pending against us that we believe are likely to have a material adverse effect on our business, results of operations and financial condition.

Item 1A. Risk Factors

We have disclosed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 the risk factors that materially affect our business, financial condition or results of operations. You should carefully consider the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2021 and the other information that appears elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2021 and in this Quarterly Report on Form 10-Q. You should be aware that these risk factors and other information may not describe every risk facing our Company. Additional risks and uncertainties not currently known to us may also materially adversely affect our business, financial condition and/or results of operations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

None.

Use of Proceeds

None.

Purchase of Equity Securities by the Issuer and Affiliated Purchasers

Share repurchase activity during the three months ended September 30, 2022 was as follows:

Period	Total Number of Shares Purchased	Weighted Average Price Paid per Share (\$)	Total Number of Shares Purchased as Part of Publicly Announced Plan or Program	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plan or Program (\$)
July 1-July 31, 2022	—	—	—	186,910,219
August 1-August 31, 2022	627,092	47.86	627,092	156,899,039
September 1-September 30, 2022	—	—	—	156,899,039
Total	627,092	47.86	627,092	

Since February 2017, our Board of Directors has authorized repurchases of up to \$1.75 billion under our existing share repurchase program. This repurchase program does not obligate us to acquire any specific number of shares and does not specify an expiration date. All shares repurchased under the plan have been retired. For additional information, see Note 17—“Capital stock” under Part I, Item 1—“Unaudited Consolidated Financial Statements” above.

Item 6. Exhibits

Exhibit Number	Description
3.1	Memorandum of Association of the Registrant (incorporated by reference to Exhibit 3.1 to Amendment No. 2 of the Registrant's Registration Statement on Form S-1 (File No. 333-142875) filed with the SEC on July 16, 2007).
3.2	Bye-laws of the Registrant (incorporated by reference to Exhibit 3.3 to Amendment No. 4 of the Registrant's Registration Statement on Form S-1 (File No. 333-142875) filed with the SEC on August 1, 2007).
22.1	List of Issuers and Guarantor Subsidiaries (incorporated by reference to Exhibit 22.1 to the Registrant's Registration Statement on Form S-3ASR (File No. 333-265204) filed with the SEC on May 25, 2022).
31.1*	Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	Inline XBRL Instance Document — the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed or furnished with this Quarterly Report on Form 10-Q.

† Indicates a management contract or compensatory plan, contract or arrangement in which any director or executive officer participates.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 9, 2022

GENPACT LIMITED

By: /s/ N.V. Tyagarajan
N.V. Tyagarajan
Chief Executive Officer

By: /s/ Michael Weiner
Michael Weiner
Chief Financial Officer

CHIEF EXECUTIVE OFFICER CERTIFICATION

I, N.V. Tyagarajan, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Genpact Limited for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 9, 2022

/s/ N.V. Tyagarajan

N.V. Tyagarajan

Chief Executive Officer

CHIEF FINANCIAL OFFICER CERTIFICATION

I, Michael Weiner, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Genpact Limited for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 9, 2022

/s/ Michael Weiner

Michael Weiner

Chief Financial Officer

Certification of the Chief Executive Officer
Pursuant to 18 U.S.C. Section 1350,
As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Genpact Limited (the "Company") on Form 10-Q for the period ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, N.V. Tyagarajan, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 9, 2022

/s/ N.V. Tyagarajan

N.V. Tyagarajan

Chief Executive Officer

Certification of the Chief Financial Officer
Pursuant to 18 U.S.C. Section 1350,
As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Genpact Limited (the "Company") on Form 10-Q for the period ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Michael Weiner, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 9, 2022

/s/ Michael Weiner

Michael Weiner

Chief Financial Officer